

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number  
**WO 02/02522 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 207/26**,  
C07C 323/62, C07D 211/60, 295/08, 211/62, 295/18,  
205/04, 295/12, 401/12, A61K 31/33, 31/16

(21) International Application Number: PCT/US01/20156

(22) International Filing Date: 22 June 2001 (22.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/606,770 29 June 2000 (29.06.2000) US

(71) Applicant: **ABBOTT LABORATORIES** [US/US]; Chad  
O377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL  
60064-6050 (US).

(72) Inventors: **LINK, James, T.**; 1630 Chicago Avenue, Apt.  
1405, Evanston, IL 60201 (US). **SORENSEN, Bryan, K.**;  
2620 N. Lewis Avenue, Waukegan, IL 60087 (US).

(74) Agents: **SHELDON, Jeffrey, G.** et al.; Sheldon & Mak,  
225 South Lake Avenue, 9th Floor, Pasadena, CA 91101  
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: ARYL PHENYCYCLOPROPYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION-INHIBITING  
ANTI-INFLAMMATORY AND IMMUNE-SUPPRESSIVE AGENTS

(57) Abstract: The present invention relates to novel cyclopropane-containing diaryl sulfide compounds that are useful for treating  
inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting  
inflammation or suppressing immune response in a mammal.



**WO 02/02522 A1**

**ARYL PHENYLCYCLOPROPYL SULFIDE DERIVATIVES AND THEIR USE  
AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY  
AND IMMUNE-SUPPRESSIVE AGENTS**

Technical Field

The present invention relates to compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these  
5 compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Background of the Invention

Inflammation results from a cascade of events that includes vasodilation  
10 accompanied by increased vascular permeability and exudation of fluid and plasma proteins. This disruption of vascular integrity precedes or coincides with an infiltration of inflammatory cells. Inflammatory mediators generated at the site of the initial lesion serve to recruit inflammatory cells to the site of injury. These mediators (chemokines such as IL-8, MCP-1, MIP-1, and RANTES, complement fragments and lipid mediators)  
15 have chemotactic activity for leukocytes and attract the inflammatory cells to the inflamed lesion. These chemotactic mediators which cause circulating leukocytes to localize at the site of inflammation require the cells to cross the vascular endothelium at a precise location. This leukocyte recruitment is accomplished by a process called cell adhesion.

Cell adhesion occurs through a coordinately regulated series of steps that allow the leukocytes to first adhere to a specific region of the vascular endothelium and then cross the endothelial barrier to migrate to the inflamed tissue (Springer, T.A., 1994, "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm", Cell, 76: 301-314; Lawrence, M.B., and Springer, T.A., 1991, "Leukocytes' Roll on a Selectin at Physiologic Flow Rates: Distinction from and Prerequisite for Adhesion Through Integrins", Cell, 65: 859-873; von Adrian, U., Chambers, J.D., McEnvoy, L.M., Bargatze, R.F., Arfos, K.E, and Butcher, E.C., 1991, "Two-Step Model of Leukocyte-Endothelial Cell Interactions in Inflammation", Proc. Nat'l. Acad. Sci. USA, 88: 7538-7542; and Ley, K., Gaehtgens, P., Fennie, C., Singer, M.S., Lasky, L.H. and Rosen, S.D., 1991, "Lectin-Like Cell Adhesion Molecule 1 Mediates Rolling in Mesenteric Venules *in vivo*", Blood, 77: 2553-2555).

These steps are mediated by families of adhesion molecules such as integrins, Ig supergene family members, and selectins which are expressed on the surface of the circulating leukocytes and on the vascular endothelial cells. The first step consists of leukocytes rolling along the vascular endothelial cell lining in the region of inflammation. The rolling step is mediated by an interaction between a leukocyte surface oligosaccharide, such as Sialylated Lewis-X antigen (Slex), and a selectin molecule expressed on the surface of the endothelial cell in the region of inflammation. The selectin molecule is not normally expressed on the surface of endothelial cells but rather is induced by the action of inflammatory mediators such as TNF- $\alpha$  and interleukin-1. Rolling decreases the velocity of the circulating leukocyte in the region of inflammation and allows the cells to more firmly adhere to the endothelial cell. The firm adhesion is accomplished by the interaction of integrin molecules that are present on the surface of the rolling leukocytes and their counter-

receptors (the Ig superfamily molecules) on the surface of the endothelial cell. The Ig superfamily molecules or CAMs (Cell Adhesion Molecules) are either not expressed or are expressed at low levels on normal vascular endothelial cells. The CAM's, like the selectins, are induced by the action of inflammatory mediators like TNF-alpha and IL-1. The final event in the adhesion process is the extravasation of leukocytes through the endothelial cell barrier and their migration along a chemotactic gradient to the site of inflammation. This transmigration is mediated by the conversion of the leukocyte integrin from a low avidity state to a high avidity state. The adhesion process relies on the induced expression of selectins and CAM's on the surface of vascular endothelial cells to mediate the rolling and firm adhesion of leukocytes to the vascular endothelium.


The interaction of the intercellular adhesion molecule ICAM-1 (cd54) on endothelial cells with the integrin LFA-1 on leukocytes plays an important role in endothelial-leukocyte contact. Leukocytes bearing high-affinity LFA-1 adhere to endothelial cells through interaction with ICAM-1, initiating the process of extravasation from the vasculature into the surrounding tissues. Thus, an agent which blocks the ICAM-1/LFA-1 interaction suppresses these early steps in the inflammatory response. Consistent with this background, ICAM-1 knockout mice have numerous abnormalities in their inflammatory responses.

The present invention discloses compounds which bind to the interaction-domain (I-domain) of LFA-1, thus interrupting endothelial cell-leukocyte adhesion by blocking the interaction of LFA-1 with ICAM-1, ICAM-3, and other adhesion molecules. These compounds are useful for the treatment or prophylaxis of diseases in which leukocyte trafficking plays a role, notably acute and chronic inflammatory

diseases, autoimmune diseases, tumor metastasis, allograft rejection, and reperfusion injury.

### Summary of the Invention


5 The present invention is directed to compounds of the structure



Formula I

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, cyano, nitro, cycloalkyl and carboxaldehyde;

10 with the proviso that at least one of  $R^1$  or  $R^3$  is selected from the group consisting of




“cis- cyclopropanoic acid”




“trans- cyclopropanoic acid”,

15



4



“*cis*- cyclopropanamide”      “*trans*- cyclopropanamide”,

wherein R<sup>6</sup> and R<sup>7</sup> are each independently selected from the group consisting

5                      of hydrogen, alkyl, carboxy, hydroxyalkyl and carboxyalkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of

hydrogen, alkyl, carboxyalkyl, alkylaminocarbonylalkyl and

dialkylaminocarbonylalkyl;

and R<sup>10</sup> and R<sup>11</sup> are each independently selected from the group consisting of

10                      hydrogen, alkyl, cycloalkyl, alkoxyalkyl, carboxyalkyl,

hydroxyalkyl, heterocyclyl, heterocyclylalkyl and heterocyclylamino;

wherein R<sup>10</sup> and R<sup>11</sup> may be joined to form a three to seven membered

heterocyclyl ring, said ring optionally being substituted with one or

more substituents R<sup>15</sup>, each substituent R<sup>15</sup> independently selected

15                      from the group consisting of alkyl, alkoxy, alkoxyalkyl, cycloalkyl,

aryl, heterocyclyl, heterocyclylcarbonyl,

heterocyclylalkylaminocarbonyl, hydroxy, hydroxyalkyl,

hydroxyalkoxyalkyl, carboxy, carboxyalkyl, carboxycarbonyl,

carboxaldehyde, alkoxyalkyl, arylalkoxyalkyl, aminoalkyl,

20                      aminoalkanoyl, carboxamido, alkoxyalkyl, carboxamidoalkyl,

cyano, tetrazolyl, alkanoyl, hydroxyalkanoyl, alkanoyloxy,

alkanoylamino, alkanoyloxyalkyl, alkanoylaminoalkyl, sulfonate,

alkylsulfonyl, alkylsulfonylaminocarbonyl, arylsulfonylaminocarbonyl

and heterocyclylsulfonylaminocarbonyl;


25                      and wherein A is an aryl or heterocyclyl group, said aryl or heterocyclyl group

having at least one substituent R<sup>12</sup>, wherein R<sup>12</sup> is selected from the

group consisting of hydrogen, halogen, alkyl, aryl, haloalkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkyl, aminoalkyl, aminocarbonyl, alkyl(alkoxycarbonylalkyl) aminoalkyl, heterocyclyl, heterocyclylalkyl, carboxaldehyde, carboxaldehyde hydrazone, carboxamide, alkoxycarbonylalkyl, carboxy, carboxyalkyl, cycloalkoxy, carboxyalkoxy, hydroxyalkylaminocarbonyl, cyano, amino, carboxythioalkoxy, carboxycycloalkoxy, thioalkoxy, carboxyalkylamino, trans-cinnamyl, heterocyclylalkylamino, and heterocyclylalkylaminocarbonyl;

wherein  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}$  and  $R^{15}$  are unsubstituted or substituted with at least one electron donating or electron withdrawing group; or a pharmaceutically-acceptable salt, optical isomer or prodrug thereof.

Presently preferred compounds of Formula I have  $R^3$  as "cis-cyclopropanamide" or "trans-cyclopropanamide";  $R^4$  and  $R^5$  each independently as hydrogen or alkyl; and  $R^1$  and  $R^2$  each independently as hydrogen, halogen, haloalkyl or nitro.



The present invention is also directed to compounds of the structure

20

## Formula II

wherein  $p$  is an integer of one to five;

q is an integer of one to four;

$R^{12}$  and  $R^{13}$ , at each occurrence, are independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, carboxyalkoxy, carboxyalkyl and heterocyclyl; and,

5  $R^{10}$  and  $R^{11}$  are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxycarbonylalkyl, carboxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl and heterocyclylamino;


wherein  $R^{10}$  and  $R^{11}$  may be joined to form a three to seven-membered heterocyclyl ring, said ring being optionally substituted with one or  
10 more substituents  $R^{15}$ , wherein  $R^{15}$  at each occurrence is independently selected from the group consisting of alkyl, alkoxy, alkoxyalkyl, cycloalkyl, aryl, heterocyclyl, heterocyclylcarbonyl, heterocyclylalkylaminocarbonyl, hydroxy, hydroxyalkyl, hydroxyalkoxyalkyl, carboxy, carboxyalkyl, carboxycarbonyl,  
15 carboxaldehyde, alkoxycarbonyl, arylalkoxycarbonyl, aminoalkyl, aminoalkanoyl, carboxamido, alkoxycarbonylalkyl, carboxamidoalkyl, cyano, tetrazolyl, alkanoyl, hydroxyalkanoyl, alkanoyloxy, alkanoylamino, alkanoyloxyalkyl, alkanoylaminoalkyl, sulfonate, alkylsulfonyl, alkylsulfonylaminocarbonyl, arylsulfonylaminocarbonyl  
20 and heterocyclylsulfonylaminocarbonyl;

wherein  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$  and  $R^{15}$  are unsubstituted or substituted with at least one electron donating or electron withdrawing group; or a pharmaceutically acceptable salt, optical isomer or pro-drug thereof.



Preferably, when compounds of Formula II have  $R^{10}$  and  $R^{11}$  joined to form a three to seven membered heterocyclyl ring, the ring may be piperidine, piperazine, morpholine, pyrrolidine or azetidine; p may be one; q may be one or two;  $R^{13}$ , at each occurrence, may be halogen or haloalkyl; and  $R^{12}$  may be halogen, alkyl, alkoxy, carboxyalkoxy, carboxyalkyl or heterocyclyl.

Presently most preferred compounds are of the structure



Formula III

wherein the circle Q represents a three to seven membered heterocyclyl ring;  
 the circle T represents a five to seven membered heterocyclyl ring;  
 r is an integer of one to three;  
 s is an integer of one to five;  
 n is an integer of one to four;  
 $R^1$  and  $R^2$ , are each independently selected from the group consisting of  
 hydrogen, halogen and haloalkyl;  
 $R^{14}$  and  $R^{15}$ , at each occurrence, are independently selected from the group  
 consisting of hydrogen, halogen, alkyl, alkoxy and carboxy; and

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>14</sup> and R<sup>15</sup> are unsubstituted or substituted with at least one electron donating or electron withdrawing group.

For presently most preferred compounds of Formula III, circle T may be pyrrolidine, n may be three; and circle Q may be a three to seven membered

5 heterocyclic ring

such as piperidine or morpholine.

The compounds represented by structural Formula I, above may be prepared by synthetic processes or by metabolic processes. Processes for the preparation of the compounds of the present invention by metabolic processes include those occurring in  
10 the human or animal body (*in vivo*) or by processes occurring *in vitro*.

The present invention is also directed to a method of treatment or prophylaxis in which the inhibition of inflammation or suppression of immune response is desired, comprising administering a therapeutic amount of a compound having Formula I; and pharmaceutical compositions containing compounds of Formula I in pharmaceutically  
15 acceptable carriers.

### Detailed Description of the Invention

20

#### *Definition of Terms*

The term "alkanoyl" as used herein refers to an alkyl group attached to the parent molecular group through a carbonyl group.

The term "alkanoylamino" as used herein refers to an alkanoyl group attached to the parent molecular group through an amino group.

The term “alkanoylaminoalkyl” as used herein refers to an alkanoylamino group attached to the parent molecular group through an alkyl group.

The term “alkanoyloxy” as used herein refers to an alkanoyl group attached to the parent molecular group through an oxygen radical.

5       The term “alkanoyloxyalkyl” as used herein refers to an alkanoyloxy group attached to the parent molecular group through an alkyl group.

The term “alkoxy” as used herein refers to an alkyl group attached to the parent molecular group through an oxygen atom.

10       The term “alkoxyalkoxy” as used herein refers to an alkoxy group attached to the parent molecular group through an alkoxy group.

The term “alkoxyalkyl” as used herein refers to an alkoxy group attached to the parent molecular group through an alkyl group.

The term “alkoxycarbonyl” as used herein refers to an alkoxy group attached to the parent molecular group through a carbonyl group.

15       The term “alkoxycarbonylalkyl” as used herein refers to an alkoxycarbonyl group attached to the parent molecular group through an alkyl group.

The term “alkyl” as used herein refers to a saturated straight or branched chain group of 1-10 carbon atoms derived from an alkane by the removal of one hydrogen atom.

20       The term “alkyl(alkoxycarbonylalkyl)amino” as used herein refers to an amino group substituted with one alkyl group and one alkoxycarbonylalkyl group.

The term “alkyl(alkoxycarbonylalkyl)aminoalkyl” as used herein refers to an alkyl(alkoxycarbonylalkyl)amino group attached to the parent molecular group through an alkyl group.

The term "alkylene" as used herein refers to a divalent group of 1-10 carbon atoms derived from a straight or branched chain alkane by the removal of two hydrogen atoms.

The term "alkylsulfonyl" as used herein refers to an alkyl radical attached to  
5 the parent molecular group through an  $\text{-SO}_2\text{-}$  group.

The term "alkylsulfonylaminocarbonyl" as used herein refers to an alkylsulfonyl group attached to the parent molecular group through an aminocarbonyl group.

The term "amino" as used herein refers to a radical of the form  $\text{-NR}_a\text{R}_b$ , or to a  
10 radical of the form  $\text{-NR}_a\text{-}$ , where  $\text{R}_a$  and  $\text{R}_b$  are independently selected from hydrogen, alkyl or cycloalkyl.

The term "aminoalkanoyl" as used herein refers to an amino group attached to the parent molecular group through an alkanoyl group.

The term "aminoalkyl" as used herein refers to an amino group attached to the  
15 parent molecular group through an alkyl group.

The term "aminocarbonyl" as used herein refers to an amino group attached to the parent molecular group through a carbonyl group.

The term "aryl" as used herein refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings. The aryl group can also be fused to a  
20 cyclohexane, cyclohexene, cyclopentane or cyclopentene ring. The aryl groups of this invention can be optionally substituted with alkyl, halogen, hydroxy, or alkoxy substituents.

The term "arylalkoxy" as used herein refers to an aryl group attached to the parent molecular group through an alkoxy group.

The term "arylalkoxycarbonyl" as used herein refers to an arylalkoxy group attached to the parent molecular group through a carbonyl group.

The term "arylsulfonyl" as used herein refers to an aryl radical attached to the parent molecular group through an -SO<sub>2</sub>- group.

5       The term "arylsulfonylaminocarbonyl" as used herein refers to an arylsulfonyl group attached to the parent molecular group through an aminocarbonyl group.

The term "carboxaldehyde" as used herein refers to the radical -CHO.

The term "carboxaldehyde hydrazone" as used herein refers to the radical -CH=N-NR<sub>c</sub>R<sub>d</sub>, where R<sub>c</sub> and R<sub>d</sub> are independently selected from hydrogen, alkyl or  
10       cycloalkyl.

The terms "carboxamide" or "carboxamido" as used herein refer to an amino group attached to the parent molecular group through a carbonyl group.

The term "carboxamidoalkyl" as used herein refers to a carboxamido group attached to the parent molecular group through an alkyl group.

15

The term "carboxy" as used herein refers to the radical -COOH.

The term "carboxyalkyl" as used herein refers to a carboxy group attached to the parent molecular group through an alkyl group.

The term "carboxyalkylamino" as used herein refers to a carboxyalkyl group  
20       attached to the parent molecular group through an amino group.

The term "carboxyalkoxy" as used herein refers to a carboxy group attached to the parent molecular group through an alkoxy group.

The term "carboxycarbonyl" as used herein refers to a carboxy group attached to the parent molecular group through a carbonyl group.

The term "carboxycycloalkoxy" as used herein refers to a carboxy group attached to the parent molecular group through a cycloalkoxy group.

The term "carboxythioalkoxy" as used herein refers to a carboxy group attached to the parent molecular group through a thioalkoxy group.

5 The term "cyano" as used herein refers to the radical -CN.

The term "cycloalkyl" as used herein refers to a monovalent saturated cyclic or bicyclic hydrocarbon group of 3-12 carbons derived from a cycloalkane by the removal of a single hydrogen atom. Cycloalkyl groups may be optionally substituted with alkyl, alkoxy, halo, or hydroxy substituents.

10 The term "cycloalkoxy" as used herein refers to a monovalent saturated cyclic or bicyclic hydrocarbon group of 3-12 atoms derived from a cycloalkane by the removal of a single hydrogen atom, linked to the parent molecular group through an oxygen atom. Cycloalkoxy groups may be optionally substituted with alkyl, alkoxy, halo or hydroxy substituents.

15 The terms "halo" or "halogen" as used herein refers to F, Cl, Br, or I.

The term "haloalkyl" as used herein refers to an alkyl group substituted with one or more halogen atoms.


The terms "heterocycle" or "heterocyclyl" represent a 4-, 5-, 6- or 7-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds. The term "heterocycle" or "heterocyclic" as used herein additionally refers to bicyclic, tricyclic and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic


20

25

heterocyclic ring. Heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnoliny, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazoliny, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholiny, oxadiazolyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazoliny, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrroliny, pyrrolyl, quinoliny, quinoxaloyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, thienyl, thiomorpholiny, triazolyl, and the like.

Heterocyclics also include bridged bicyclic groups where a monocyclic heterocyclic group is bridged by an alkylene group such as



Heterocyclics also include compounds of the formula  where X\* and Z\* are independently selected from -CH<sub>2</sub>-, -CH<sub>2</sub>NH-, -CH<sub>2</sub>O-, -NH- and -O-, with the proviso that at least one of X\* and Z\* is not -CH<sub>2</sub>-, and Y\* is selected from -C(O)- and -(C(R''))<sub>v</sub> -, where R'' is hydrogen or alkyl of one to four carbons, and v is 1-3. These heterocycles include 1,3-benzodioxolyl, 1,4-benzodioxanyl, 1,3-benzimidazol-2-one and the like. The heterocycle groups of this invention can be optionally substituted with alkyl, halogen, carboxy, hydroxy or alkoxy substituents.

The term "heterocyclalkyl" as used herein refers to a heterocyclic group attached to the parent molecular group through an alkyl group.

The term "heterocyclalkylamino" as used herein refers to a heterocyclalkyl group attached to the parent molecular group through an amino group.

5       The term "heterocyclalkylaminocarbonyl" as used herein refers to a heterocyclalkylamino group attached to the parent molecular group through a carbonyl group.

The term "heterocyclamino" as used herein refers to a heterocycl group attached to the parent molecular group through an amino group.

10       The term "heterocyclcarbonyl" as used herein refers to a heterocycl group attached to the parent molecular group through a carbonyl group.

The term "heterocyclsulfonyl" as used herein refers to a heterocycl radical attached to the parent molecular group through an -SO<sub>2</sub>- group.

15       The term "heterocyclsulfonylaminocarbonyl" as used herein refers to a heterocyclsulfonyl group attached to the parent molecular group through an aminocarbonyl group.

The term "hydroxyalkanoyl" as used herein refers to a hydroxy radical attached to the parent molecular group through an alkanoyl group.

20       The term "hydroxyalkoxy" as used herein refers to a hydroxy radical attached to the parent molecular group through an alkoxy group.

The term "hydroxyalkoxyalkyl" as used herein refers to a hydroxyalkoxy group attached to the parent molecular group through an alkyl group.

The term "hydroxyalkyl" as used herein refers to a hydroxy radical attached to the parent molecular group through an alkyl group.



The term "hydroxyalkylaminocarbonyl" as used herein refers to a hydroxyalkyl group attached to the parent molecular group through an aminocarbonyl group.

5 The term "perfluoroalkyl" as used herein refers to an alkyl group in which all of the hydrogen atoms have been replaced by fluoride atoms.

The term "phenyl" as used herein refers to a monocyclic carbocyclic ring system having one aromatic ring. The phenyl group can also be fused to a cyclohexane or cyclopentane ring. The phenyl groups of this invention can be optionally substituted with alkyl, halogen, hydroxy or alkoxy substituents.

10 The term "pharmaceutically-acceptable prodrugs" as used herein represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended  
15 use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

The term "prodrug," as used herein, represents compounds which are rapidly transformed *in vivo* to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and  
20 in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. The term "sulfonate" as used herein refers to the radical -SO<sub>3</sub>H

The term "tetrazole" or "tetrazolyl" as used herein refers to the heterocyclic radical  $\text{-CN}_4\text{H}$ .

The term "thioalkoxy" as used herein refers to an alkyl group attached to the parent molecular group through a sulfur atom.

5       The term "trans-cinnamyl" as used herein refers to an acrylamido group (aminocarbonylethenyl) attached to the parent molecular group through C-3 of the acrylamido group, such that the aminocarbonyl and the parent molecular group exist in a trans relationship about the ethenyl group.

      The term "lower" refers to a  $\text{C}_1\text{-C}_6$  unit for a particular functionality. For  
10   example, "lower alkyl" means  $\text{C}_1\text{-C}_6$  alkyl.

      Use of the above terms is meant to encompass substituted and unsubstituted moieties. Substitution may be by one or more groups such as alcohols, ethers, esters, amides, sulfones, sulfides, hydroxyl, nitro, cyano, carboxy, amines, heteroatoms, lower alkyl, lower alkoxy, lower alkoxycarbonyl, alkoxyalkoxy, acyloxy, halogen,  
15   trifluoromethoxy, trifluoromethyl, aralkyl, alkenyl, alkynyl, aryl, carboxyalkoxy, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, alkylheterocyclyl, heterocyclylalkyl, oxo, arylsulfonaminocarbonyl or any of the substituents of the preceding paragraphs or any of those substituents either attached directly or by suitable linkers. The linkers are typically short chains of 1-3 atoms containing any  
20   combination of  $\text{-C-}$ ,  $\text{-C(O)-}$ ,  $\text{-NH-}$ ,  $\text{-S-}$ ,  $\text{-S(O)-}$ ,  $\text{-O-}$ ,  $\text{-C(O)O-}$  or  $\text{-S(O)-}$ . Rings may be substituted multiple times.

      The terms "electron-withdrawing" or "electron-donating" refer to the ability of a substituent to withdraw or donate electrons relative to that of hydrogen if hydrogen occupied the same position in the molecule. These terms are well-understood by one

skilled in the art and are discussed in Advanced Organic Chemistry by J. March, 1985, pp. 16-18, incorporated herein by reference.

Electron withdrawing groups include halo, nitro, carboxyl, lower alkenyl, lower alkynyl, carboxaldehyde, carboxyamido, aryl, quaternary ammonium and trifluoromethyl among others. Electron donating groups include such groups as hydroxy, lower alkyl, amino, lower alkylamino, di(lower alkyl)amino, aryloxy, mercapto, lower alkylthio, lower alkylmercapto and disulfide among others. One skilled in the art will appreciate that the aforesaid substituents may have electron donating or electron withdrawing properties under different chemical conditions. Moreover, the present invention contemplates any combination of substituents selected from the above-identified groups.

The most preferred electron donating or electron withdrawing substituents are halo, nitro, alkanoyl, carboxaldehyde, arylalkanoyl, aryloxy, carboxyl, carboxamide, cyano, sulfonyl, sulfoxide, heterocyclyl, guanidine, quaternary ammonium, lower alkenyl, lower alkynyl, sulfonium salts, hydroxy, lower alkoxy, lower alkyl, amino, lower alkylamino, di(lower alkylamino), amine lower mercapto, mercaptoalkyl, alkylthio and alkylidithio.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a combination of the specified ingredients in the specified amounts.

Compounds of the present invention can exist as stereoisomers wherein asymmetric or chiral centers are present. These compounds are designated by the symbols "R" or "S," depending on the configuration of substituents around the chiral carbon atom. The present invention contemplates various stereoisomers and mixtures

thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers are designated ( $\pm$ ). Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by  
5 preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation  
10 employing an optically active resolving agent, or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.

Geometric isomers can also exist in the compounds of the present invention. The present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double  
15 bond or arrangement of substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the Z or E configuration wherein the term "Z" represents substituents on the same side of the carbon-carbon double bond and the term "E" represents substituents on opposite sides of the carbon-carbon double bond. The arrangement of substituents around a carbocyclic ring are  
20 designated as cis or trans wherein the term "cis" represents substituents on the same side of the plane of the ring and the term "trans" represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated cis/trans.

The compounds of this invention are diaryl sulfides, which are substituted with a cyclopropanoyl or cyclopropanamido moiety. The cyclopropanoyl or cyclopropanamido functionality may be placed either ortho- or para- to the linking sulfur atom, although para-substitution is preferable. Appropriate substitution of both aromatic rings is tolerated, and can be used to modulate a variety of biochemical, physicochemical and pharmacokinetic properties. In particular the amide or carboxyl moiety is readily modified; a variety of secondary and tertiary amides are active, and alternatively a heterocyclic ring may be attached at this position. Modifications of the amide or carboxyl functionality are particularly useful in modulating physicochemical and pharmacokinetic properties.

As is apparent from the foregoing descriptions, the compounds of Formula I are useful in a variety of forms, i.e., with various substitutions as identified. Examples of particularly desirable compounds are quite diverse, and many are mentioned herein. Included are compounds in which  $R^1$  is a "cis- cyclopropane" or a "trans- cyclopropane", and  $R^3$  is hydrogen; or where  $R^3$  is a "cis- cyclopropane" or a "trans- cyclopropane", and  $R^1$  is hydrogen, or  $R^1$ ,  $R^2$ , and  $R^4$  are each independently hydrogen or alkyl, and  $R^5$  is halogen, haloalkyl or nitro. Further preferred compounds include those as above wherein  $R^{10}$  and  $R^{11}$  are each independently hydrogen, alkyl, cycloalkyl, alkoxy carbonyl alkyl, hydroxyalkyl, or heterocyclalkyl, or where  $NR^{10}R^{11}$  is heterocyclalkyl or substituted heterocyclalkyl, and where A is aryl, substituted aryl, heterocyclalkyl, or substituted heterocyclalkyl.

When  $R^{10}$  and  $R^{11}$  are joined to form a ring, the ring will be heterocyclalkyl, due to the presence of the nitrogen from which  $R^{10}$  and  $R^{11}$  are appended. Depending upon which  $R^{10}$  and  $R^{11}$  substituents are chosen, the ring formed may contain at least one additional heteroatom, such as oxygen, nitrogen or sulfur.

In Formula III, circle Q represents a heterocyclyl, nitrogen containing ring.

This ring may contain at least one additional heteroatom, such as oxygen, nitrogen or sulfur; and may be substituted or unsubstituted.

In Formula III, circle T represents a heterocyclyl, amide containing ring. This  
 5 ring may contain at least one additional heteroatom such as oxygen, nitrogen or sulfur, and may be substituted or unsubstituted.

Compounds of the present invention include, but are not limited to: (±)-(2-bromophenyl)[2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl)[2,3-dichloro-4-(*trans*-(carboxymethylamino)carbonyl) cycloprop-1-yl)phenyl)sulfide, (±)-  
 10 (2-isopropylphenyl)[2,3-dichloro-4-(*trans*-(2-(3-carboxypiperidine))carbonyl) cycloprop-1-yl)phenyl)sulfide, (±)-(2-(2-carboxyethyl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-morpholin-1-ylphenyl) [2-chloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-piperidin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-pyrrolidin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(3-morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-morpholin-1-ylphenyl) [2,3-dichloro-4-(*trans*-(2-carboxycycloprop-1-yl)phenyl)sulfide, (±)-(2-morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-propyl-N-methylamino) carbonyl) cycloprop-1-yl)phenyl)sulfide, (

(±)-(2-bromophenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-bromophenyl) [2,3-dichloro-4-(*trans*-(2-carboxycycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-carboxyethylamino) carbonyl)cycloprop-1-yl)phenyl)sulfide, (

5 (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(3-carboxypropyl amino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl] sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-

10 (*trans*-(2-(morpholin-1-yl)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(4-acetylpiperazin-1-yl)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(pyrrolidin-1-yl)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-

15 (*trans*-(2-(cyclobutylaminocarbonyl) cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(azetidin-1-yl)carbonyl) cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-morpholin-1-ylethyl)carbonyl) cycloprop-1-yl)phenyl)sulfide, (2-(3-carboxypiperidin-1-yl)phenyl)

20 [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (2-(morpholin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl) cycloprop-1-yl)phenyl)sulfide, (2-(3-carboxypiperidin-1-yl)phenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-

25 yl)phenyl)sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-(2-(carboxymethylamino)

carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxyethylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypropylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl) [2,3-dichloro-4-(*trans*-2-(2-carboxyethylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypropylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl) [2,3-dichloro-4-(*trans*-2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide and (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide.

#### Abbreviations

Abbreviations which have been used in the schemes and the examples which follow are: DCM for methylene dichloride; EWG for electron withdrawing group; NMP for N-methylpyrrolidinone; sat. for saturated; THF for tetrahydrofuran; TFA for trifluoroacetic acid; ; BINAP for 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl; DMSO for dimethylsulfoxide; DMF for dimethylformamide; TLC for thin layer chromatography; HPLC for high pressure liquid chromatography; APCI for



atmospheric pressure chemical ionization; ESI for electrospray ionization; DCI for direct chemical ionization; LFA for lymphocyte function-associated antigen; and ICAM for intercellular adhesion molecule.

5

*Pharmaceutical Compositions and Methods of Treatment*

The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more pharmaceutically-acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically-acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by

the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

5           Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically-acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example,  
10   carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example,  
15   cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (I) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

          Solid compositions of a similar type may also be employed as fillers in soft  
20   and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

          The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain  
25   opacifying agents and can also be of a composition that they release the active

ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate,  
5 with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and  
10 emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

15 Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and  
20 sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a

suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically-acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

The compounds of the present invention may be used in the form of pharmaceutically-acceptable salts derived from inorganic or organic acids. By “pharmaceutically-acceptable salt” is meant those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically-acceptable salts are well-known in the art. For example, S. M. Berge, *et al.* Describe pharmaceutically-acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 et seq. The salts may be prepared *in situ* during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid. Representative acid addition salts include, but are not limited to acetate,

adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 5 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like 10 dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as 15 hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

Basic addition salts can be prepared *in situ* during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a 20 pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically-acceptable basic addition salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, 25 tetramethylammonium, tetraethylammonium, methylamine, dimethylamine,

trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically-acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.


Generally dosage levels of about 0.1 to about 50 mg, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally or intravenously to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.

25

### *Preparation of Compounds of this Invention*

The compounds and processes of the present invention may be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention can be prepared.

5


Scheme 1

Scheme 1 describes the synthesis of a typical cyclopropane-substituted diaryl sulfide **5** through an aldehyde intermediate **2**. Aldehyde **2** is prepared by reaction of a thiophenol (for example 2,4-dichlorothiophenol, 2-bromothiophenol, or the like) with halo-substituted benzaldehyde derivative **1** (e.g. 2-chlorobenzaldehyde, 3-chloro,4-fluorobenzaldehyde, or the like) in the presence of base (e.g. sodium carbonate, triethylamine, or the like) and a polar solvent (e.g. dimethylformamide, dimethylsulfoxide, or the like). The aldehyde group is homologated to the corresponding cinnamic ester **3**, using an acetate equivalent (for example, malonic acid, triethoxyphosphonoacetate, or the like) in the presence of an appropriate base and solvent. The cyclopropane acid **4** is prepared by treatment with trimethylsulfoxonium iodide in the presence of base (for example, NaH) followed by hydrolysis of the intermediate ester (for example using sodium hydroxide in alcohol). The acid group is activated (for example using thionyl chloride, or




dicyclohexylcarbodiimide and N-hydroxysuccinimide, or the like) and reacted with a primary or secondary amine (for example, 6-aminohexanol, pyrrolidone-3-propylamine, or the like) to provide the desired analog 5. In one variant, a haloacetophenone can replace benzaldehyde 2; the resultant cyclopropanes 5 are substituted with a methyl group.

### Scheme 2




Alternatively, the order of these coupling steps may be reversed (Scheme 2). A substituted halocyclopropane acid 6 (e.g. 3-chloro-2-nitrocyclopropane acid or the like) may be coupled with a primary or secondary amine (e.g. N-acetylpiperazine or the like) as described above to give the corresponding amide 7. The halo-group can then be displaced with a substituted thiophenol in the presence of base to provide the product 8.

### Scheme 3



A number of the compounds described herein may be prepared from intermediate halides or triflates like **9** (Scheme 3) Heck reaction (for example, using palladium acetate and tri-*o*-tolylphosphine) with alkenes (like methyl acrylate) followed by olefin functionalization (e.g. hydrogenation utilizing palladium on carbon) provides analogs with structures related to **10**. Alternatively the halides or triflates may be coupled with amines (primary and secondary) and alcohols under transition metal catalysis (for example tris(dibenzylideneacetone)dipalladium(0) and ( $\pm$ )-2,2' bis(diphenylphosphino)-1,1'-binaphthyl) to provide analogs with structures related to **11**.


10



Cyclopropanes like **14** may be prepared from halo(or triflo)-substituted derivatives **12** by palladium-mediated coupling [e.g. using tetrakis(triphenylphosphine) palladium (0), Pd<sub>2</sub>(dba)<sub>3</sub>, or the like] with alkene derivatives **13** (Scheme 4). Cyclopropanation (e.g. ethyl diazoacetate and rhodium catalyst) then yields cyclopropanes **14**. Direct coupling with cyclopropane derivatives also yields diarylsulfide cyclopropanes **14**.

20

## Scheme 5




5 It is also possible to assemble cyclopropane-substituted diaryl sulfides in a “reverse” sense (Scheme 5). Thus, for example, compound 15, prepared as described in Scheme 1, may be deprotected by treatment with base (e.g. potassium t-butoxide or the like) to provide thiolate anion 16, which may be reacted with an activated haloarene (e.g. 2,3-dichlorobenzaldehyde, 3-chloro,4-fluorobenzaldehyde or the like) to provide the corresponding product 17. Alternatively, this same thiolate anion may be coupled with unactivated aryl halides (e.g. aryl bromide or aryl iodides) using a metal-catalyzed Ullman coupling procedure (for example, using a palladium or nickel catalyst) to give product 18.

15 The compounds and processes of the present invention will be better understood in connection with the following examples which are intended as an illustration of and not a limitation upon the scope of the invention.


In the Examples, a mixture of isomers is referred to as a compound number, such as compound 1, and the individual isomers are given an A designation (indicating the first isomer, i.e. 1A) or a B designation (indicating the second isomer, i.e. 1B).

Example 1

(±)-(2-Bromophenyl)[2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **19**, was synthesized according to the following procedure.


**19**

1A. First, 4-[(2-Bromophenyl)thio]-3-trifluoromethyl-benzaldehyde, **20**, was synthesized as follows.

**20**


To a stirred solution of potassium carbonate (4.50 g, 32.5 mmol) in 100 mL of anhydrous NMP was added 2-bromothiophenol (3.9 mL, 32.5 mmol), followed by 4-fluoro-3-trifluoromethylbenzaldehyde (5.0 g, 26 mmol). The mixture was heated under nitrogen atmosphere at 85 °C for 12 hours. The reaction mixture was cooled to room temperature and partitioned between ether and water. The aqueous layer was extracted with ether and the combined organic layers washed with water (2x) and brine, dried over sodium sulfate, and condensed *in vacuo*. The crude product was purified by flash chromatography on silica gel, eluting with 4:1 hexane:ethyl acetate, to give 8.70 g (24.1 mmol, 93%) of the title compound **20** as a yellow oil.

1B. Next, (2-Bromophenyl)[2-trifluoromethyl-4-(*E*-(ethoxycarbonyl)ethenyl)phenyl)sulfide, **21**, was synthesized as follows.



NaH (1.80 g, 45 mmoles, 60 % dispersion) was added to a solution of (ethoxycarbonylmethyl)triphenylphosphonium chloride (21.65 g, 45.0 mmoles) in THF (112 mL). After one hour, a solution of the compound **20** (8.70 g, 24.9 mmol) in THF (60 mL) was added dropwise. After one hour the reaction was quenched with sat.  $\text{NH}_4\text{Cl}$  (50 mL) and was concentrated *in vacuo*. The crude products were dissolved in  $\text{Et}_2\text{O}$ , washed with  $\text{H}_2\text{O}$  and brine, dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel eluting with 6.5:1 hexane:ethyl acetate yielded 9.09 g (21.1 mmol, 85 %) of the title compound **21** as a yellow oil.

1C. Then ( $\pm$ )-(2-Bromophenyl)[2-trifluoromethyl-4-*trans*-(2-carboxycycloprop-1-yl)phenyl]sulfide, **22**, was synthesized as follows.



NaH (0.7382g, 18.5 mmoles, 60% dispersion) was added to a solution of trimethylsulfoxonium iodide in DMSO (74 mL). After one hour, a solution of the compound **21** (7.58 g, 17.6 mmol) in DMSO (17.6 mL) was added dropwise. The reaction turned red and was stirred for 12 hours. The crude products were diluted with  $\text{Et}_2\text{O}$  and then rinsed with sat.  $\text{NH}_4\text{Cl}$ ,  $\text{H}_2\text{O}$ , and brine. The organic layer was then dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated *in vacuo*. Purification by flash

chromatography on silica gel using 10:1→4:1 hexane:ethyl acetate as eluant provided 5.09 g (11.4 mmol, 65%) of cyclopropyl ester. A solution of NaOH (10%, 5.0 mL) was added to a solution of cyclopropyl ester (2.5 g, 5.61 mmol) in EtOH (20 mL) and THF (5 mL). After one hour, the reaction was quenched with sat. NH<sub>4</sub>Cl and concentrated *in vacuo*. The reaction mixture was extracted with EtOAc, rinsed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated *in vacuo* to provide the title compound **22** (2.29 g, 98%) as a white solid.


1D. Finally, (±)-(2-Bromophenyl)[2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **19**, was synthesized as follows.

1-(3-aminopropyl)-2-pyrrolidinone (0.94 mL, 6.7 mmol) was added to a solution of the compound **22** (2.0 g, 4.79 mmol), 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (1.1485 g, 5.99 mmol), and 1-hydroxybenzotriazole hydrate (0.9716 g, 7.2 mmol) in DMF (18 mL). The reaction was stirred at room temperature overnight. The crude products were diluted with EtOAc and rinsed with sat. NH<sub>4</sub>Cl, H<sub>2</sub>O (2x), and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification by silica gel chromatography using 9:1 CH<sub>2</sub>Cl<sub>2</sub>:MeOH as the eluant yielded 2.4596 g (95%) of the title compound **19**. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.61 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.50 (d, *J* = 1.8 Hz, 1H), 7.29 (d, *J* = 7.7 Hz, 1H), 7.08-7.22 (m, 3H), 6.96 (dd, *J* = 7.5, 1.7 Hz, 1H), 5.70 (br s, 1H), 3.45 (m, 4H), 3.35 (m, 2H), 2.55 (m, 1H), 2.45 (m, 2H), 2.04-2.18 (m, 2H), 1.66-1.83 (m, 4H), 1.25-1.31 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 176.2, 171.2, 141.9, 135.6, 133.2, 131.3, 130.0, 128.0, 125.02, 125.0, 124.9, 124.8, 124.7, 124.1, 47.4, 39.5, 35.7, 30.8, 27.0, 26.3, 24.1, 17.9, 16.2. MS (APCI) (M+H)<sup>+</sup> at *m/z* 543, 421. Anal. Calc'd for C<sub>24</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>SBrF<sub>3</sub>· 1.3 H<sub>2</sub>O: C, 51.03; H, 4.75; N, 4.96. Found:

C, 50.95; H, 4.39; N, 4.94.


**Example 2**

(±)-(2-Isopropylphenyl)[2,3-dichloro-4-(*trans*-  
5 (carboxymethylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, **23**, was synthesized  
in the following manner.



**23**

10 2A. First, (2-Isopropylphenyl)[2,3-dichloro-4-formylbenzene]sulfide, **24**, was  
synthesized in the following manner.




**24**

15 Trifluoromethanesulfonic anhydride (5.74 mL, 34.1 mmol) was added to a  
suspension of 2,3-dichloro-4-hydroxy-benzaldehyde (synthesized according to the  
procedure of Bicking et al., *J. Med. Chem.*, 1976, 19, 534, 5.92 g, 31.0 mmol) in  
20 pyridine (31 mL) at 0 °C. The reaction was warmed to room temperature and stirred  
for one hour. The crude products were poured onto ice and extracted with Et<sub>2</sub>O (2x).  
The combined organics were washed with 1N HCl (2x) and brine before being dried  
over Na<sub>2</sub>SO<sub>4</sub>. Concentration provided 10 g of the corresponding crude triflate. 2-  
isopropylbenzenethiol (90% pure, 2.6 mL, 15.5 mmol) and N,N-  
25 diisopropylethylamine (5.4 mL, 31.0 mmol) were added to a solution of crude

triflate (5.0 g, 15.5 mmol) in CH<sub>3</sub>CN (15.5 mL). After 20 minutes, the reaction was quenched with sat. NH<sub>4</sub>Cl. The crude products were extracted with Et<sub>2</sub>O and washed with sat. NH<sub>4</sub>Cl, H<sub>2</sub>O (2x), and brine. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography on silica gel eluting with

5 20:1→10:1 hexane:ethyl acetate provided the title compound **24** (3.71 g, 74%).

2B. Then (±)-(2-Isopropylphenyl)[2,3-dichloro-4-*trans*-(2-carboxycycloprop-1-yl)phenyl]sulfide, **25**, was synthesized as follows.



**25**

10 **25** was prepared from the compound **24** by the procedures described in Example 1, steps B and C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.42 (m, 3H), 7.22 (m, 1H), 6.74 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 3.46 (m, 1H), 2.76 (m, 1H), 1.74 (m, 1H), 1.65 (m, 1H), 1.32 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 6H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 75 MHz) δ 179.4, 152.8, 139.4, 136.6, 135.2, 134.9, 130.4, 192.0, 128.0, 127.16, 126.81,

15 125.22, 124.9, 30.9, 25.7, 23.8, 22.7, 16.1; MS (APCI) (M+HCl)<sup>+</sup> at *m/z* 417.

2C. Then (±)-(2-Isopropylphenyl)[2,3-dichloro-4-(*trans*-(carboxymethylamino)carbonyl)cycloprop-1-yl]phenyl]sulfide, **23**, was prepared as follows.

N,N-Diisopropylethylamine (0.11 mL, 0.63 mmol) was added to a solution


20 of the compound **25** (0.1000 g, 262 μmol), 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (0.0704 g, 0.367 mmol), 1-hydroxybenzotriazole hydrate (0.0602 g, 0.4457 mmol), and glycine methyl ester hydrochloride (0.0658 g, 0.52 mmol) in DMF (0.66 mL). The reaction was stirred at room temperature



overnight. The crude products were diluted with EtOAc and rinsed with sat.  $\text{NH}_4\text{Cl}$ ,  $\text{H}_2\text{O}$  (2x), and brine. The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The crude products were dissolved in THF (1.0 mL) and EtOH (1.0 mL) and treated with 2N NaOH until ester hydrolysis was complete by TLC. The solution was poured into 2N HCl and extracted with EtOAc (2x). The combined organic layers were rinsed with brine, dried over  $\text{Na}_2\text{SO}_4$ , concentrated, and purified by preparative HPLC. Reverse phase preparative HPLC was performed on a YMC Guardpak ODS column using acetonitrile and .1% trifluoroacetic acid in water as eluant to give 0.0962 g of the title compound **23** (0.22 mmol, 84%).  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  7.42 (m, 3H), 7.22 (m, 1H), 6.74 (d,  $J = 8.5$  Hz, 1H), 6.40 (d,  $J = 8.5$ , 1H), 6.22 (t,  $J = 6.8$ , 1H), 4.17 (dd,  $J = 5.1, 1.7$  Hz, 2H), 3.46 (m, 1H), 2.67 (m, 1H), 1.64 (m, 1H), 1.52 (m, 1H), 1.25 (m, 1H), 1.18 (d,  $J = 6.8$  Hz, 6H); MS (APCI) ( $\text{M}$ ) $^+$  at  $m/z$  440, 438; Anal. Calc'd for  $\text{C}_{21}\text{H}_{21}\text{NO}_3\text{SCl}_2 \cdot 0.1 \text{ H}_2\text{O} \cdot 0.15 \text{ TFA}$ : C, 55.95; H, 4.71; N, 3.06. Found: C, 55.94; H, 4.69; N, 3.13.

### Example 3

(±)-(2-Isopropylphenyl)[2,3-dichloro-4-(*trans*-(2-(3-cycloprop-1-yl)phenyl)sulfide), **26**, was synthesized according to the following procedure.



**26**

DMF (1 drop) was added to a solution of the compound **25** (0.65 g, 1.7 mmol) and oxalyl chloride (0.16 mL, 1.87 mmol) in  $\text{CH}_2\text{Cl}_2$  (4.3 mL). The

solution was stirred at room temperature for two hours, concentrated *in vacuo*, and azeotropically dried with toluene (2x) on a rotary evaporator. The resulting crude acid chloride was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5.2 mL). A portion of the solution (0.4 mL) was placed in a separate reaction vessel via syringe and was treated with ethyl  
5 nipecotate (0.081 mL, 0.2622 mmoles) and N,N-diisopropylethylamine. After stirring for one hour the reaction was concentrated *in vacuo*. The crude products were dissolved in THF (1.0 mL) and EtOH (1.0 mL) and treated with 2N NaOH until ester hydrolysis was complete by TLC. The solution was poured into 2N HCl and extracted with EtOAc (2x). The combined organic layers were rinsed with brine,  
10 dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by preparative HPLC. Preparative HPLC was performed as in Example 2, step C to give 0.0555g of the title compound **26** (86%) as a white solid. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300MHz) δ 7.44 (m, 3H), 7.22 (m, 1H), 6.77 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 4.51 (m, 1H), 4.08 (m, 1H), 3.88 (m, 2H), 3.48 (m, 1H), 3.24 (m, 2H), 2.58 (m, 2H), 2.04-2.22 (m, 3H), 1.64-1.82 (m, 2H),  
15 1.22 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 494, 492 Anal. Calcd for C<sub>25</sub>H<sub>27</sub>NO<sub>3</sub>SCl<sub>2</sub> · 0.15 H<sub>2</sub>O · 0.15 TFA: C, 59.32; H, 5.40; N, 2.73. Found: C, 59.32; H, 5.44; N, 2.54.

#### Example 4

20 (2-Bromophenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, Isomer #1, **19A**, was synthesized according to the following procedure.

Resolution of the compound **19** using a Chiralpak AD HPLC column eluting with 90:10 hexane:EtOH gave baseline resolution of two enantiomers which were  
25 both >98% ee by HPLC. The earlier eluting isomer is denoted isomer #1 (**19A**) and


the later eluting isomer is denoted isomer #2 (**19B**). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300MHz) δ 8.14 (t, *J* = 5.5 Hz, 1H), 7.71 (dd, *J* = 8.1, 1.5 Hz, 1H), 7.67 (d, *J* = 1.8 Hz, 1H), 7.46 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.33 (dt, *J* = 7.7, 1.5 Hz, 1H), 7.22 (dt, *J* = 7.7, 1.5 Hz, 1H), 6.85 (dd, *J* = 7.7, 1.5, 1H), 3.28 (m, 4H), 3.17 (t, *J* = 7.2, 2H), 3.05 (m, 2H), 2.41 (m, 1H), 2.20 (t, *J* = 6.6 Hz, 2H), 1.92 (m, 1H), 1.58 (m, 2H), 1.43 (m, 1H), 1.35 (m, 1H), MS (APCI) (M)<sup>+</sup> at *m/z* 543, 541.

#### Example 5

(2-Bromophenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, Isomer #2, **19B**, was also isolated from the procedure described in Example 4. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300 MHz) δ 8.14 (t, *J* = 5.5 Hz, 1H), 7.71 (dd, *J* = 8.1, 1.5 Hz, 1H), 7.67 (d, *J* = 1.8 Hz, 1H), 7.46 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.33 (dt, *J* = 7.7, 1.5 Hz, 1H), 7.22 (dt, *J* = 7.7, 1.5 Hz, 1H), 6.85 (dd, *J* = 7.7, 1.5, 1H), 3.28 (m, 4H), 3.17 (t, *J* = 7.2, 2H), 3.05 (m, 2H), 2.41 (m, 1H), 2.20 (t, *J* = 6.6 Hz, 2H), 1.92 (m, 1H), 1.58 (m, 2H), 1.43 (m, 1H), 1.35 (m, 1H), MS (APCI) (M)<sup>+</sup> at *m/z* 543, 541; FAB HRMS (M+H)<sup>+</sup> calc for C<sub>24</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>F<sub>3</sub>S<sub>1</sub>Br<sub>1</sub> 543.0752, obs. 543.0762; Anal. Calc'd for C<sub>24</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>SF<sub>3</sub>Br · 1.6 H<sub>2</sub>O: C, 50.55; H, 4.81; N, 4.91. Found: C, 50.33; H, 4.28; N, 4.76.

#### Example 6


(±)-(2-(2-carboxyethyl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **27**, was synthesized according to the following procedure.



Triethylamine (0.074 mL, 0.53 mmoles) and methyl acrylate (0.048 mL, 0.53  
 5 mmoles) were added to a solution of the compound **19** (0.1200 g, 0.2216 mmoles),  
 palladium acetate (0.0025 g, 0.011 mmoles), and tri(*o*-tolyl)phosphine (0.0202 g,  
 0.0604 mmoles) in NMP (1.0 mL). The reaction was heated to 85 °C for ten hours.  
 The reaction was diluted with Et<sub>2</sub>O and washed with sat. NH<sub>4</sub>Cl, H<sub>2</sub>O (2x), and brine.  
 The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. The crude  
 10 products were dissolved in THF (1.4 mL) and EtOH (1.4 mL) and were treated with  
 2N NaOH until ester hydrolysis was complete by TLC. The reaction mixture was  
 then poured into 2N HCl and extracted with EtOAc (2x). The combined organics  
 were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. A solution of the crude products  
 and 10% palladium on carbon (0.0400 g) in EtOAc (1.0 mL) and MeOH (1.0 mL)  
 15 were stirred vigorously under a hydrogen atmosphere overnight. The reaction was  
 then placed under a nitrogen atmosphere and the crude products filtered through a 1''  
 pad of silica gel with 9:1 CH<sub>2</sub>Cl<sub>2</sub>:MeOH. Purification by preparative HPLC provided  
 the desired acid **27** (0.0627 g, 53%). <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.12 (br m,  
 1H), 7.21-7.56 (m, 6H), 6.92 (d, *J* = 8.5 Hz, 1H), 3.18 (m, 2H), 3.04 (m, 2H), 3.30 (m,  
 20 2H), 2.90 (t, *J* = 7.7 Hz, 2H), 2.33 (m, 2H), 2.19 (t, *J* = 8.3 Hz, 2H), 1.89 (m, 4H),  
 1.58 (m, 2H), 1.38 (m, 1H), 1.29 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z* 535.

Example 7


(±)-(2-Morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **28**, was synthesized according to the following procedure.



Morpholine (0.041 mL, 0.47 mmoles) was added to a solution of the compound **19** (0.2050g, 0.38 mmoles), tris(dibenzylideneacetone)bispalladium (0.0086g, 0.0094 mL), (±)-BINAP (0.0176 g, 0.0283 mmoles), and sodium *tert*-butoxide (0.0509 g, 0.53 mmoles) in toluene (1.5 mL). The reaction was stirred at room temperature for 20 minutes and then at 80 °C for 12 hours. The crude products were filtered through a pad of silica gel with EtOAc followed by 9:1 CH<sub>2</sub>Cl<sub>2</sub>:MeOH and purified by preparative HPLC to provide the product **28** (0.1740 g, 84%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.45 (d, *J* = 1.8 Hz, 1H), 7.07-7.24 (m, 4H), 6.97 (dt, *J* = 7.5, 1.5 Hz, 1H), 6.84 (dd, *J* = 8.1 1.5 Hz, 1H), 3.78 (t, *J* = 4.6 Hz, 4H), 3.42 (m, 4H), 3.17-3.37 (m, 4H), 3.05 (t, *J* = 4.4 Hz, 4H), 2.53 (m, 1H), 2.47 (m, 2H), 2.09 (m, 2H), 1.72 (m, 3H), 1.25 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z* 548; Anal. Calc'd for C<sub>28</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub>SF<sub>3</sub> · 2.7 H<sub>2</sub>O: C, 56.40; H, 6.32; N, 7.05. Found: C, 56.29; H, 5.24; N, 6.61.

Example 8


(±)-(2-Morpholin-1-ylphenyl) [2-chloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **29**, was synthesized according to the following procedure.



The title compound **29** was prepared by the procedure described in Examples 1 and 7, substituting 3,4-dichlorobenzaldehyde for 4-fluoro-3-trifluoromethylbenzaldehyde. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.14 (t, *J* = 5.5 Hz, 1H), 7.42 (d, *J* = 1.8 Hz, 1H), 7.28 (d, *J* = 8.1 Hz, 1H), 7.12-7.26 (m, 3H), 7.00 (m, 1H), 6.65 (dd, *J* = 7.1, 1.1 Hz, 1H), 3.67 (t, *J* = 4.4 Hz, 4H), 3.30 (m, 2H), 3.17 (t, *J* = 7.2 Hz, 1H), 3.04 (m, 2H), 2.96 (t, *J* = 4.6 Hz, 4H), 2.29 (m, 1H), 2.20 (t, *J* = 8.1 Hz, 2H), 1.92 (m, 3H), 1.58 (m, 2H), 1.48 (m, 1H), 1.39 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z* 514.

#### Example 9

(±)-(2-Piperidin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **30**, was synthesized according to the following procedure.




## 30

The title compound **30** was prepared by the procedure described in Example 7, substituting piperidine for morpholine. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.15 (t, *J* = 7.1 Hz, 1H), 7.61 (d, *J* = 1.8 Hz, 1H), 7.41 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.18 (m, 2H), 6.95 (m, 1H), 6.61 (dd, *J* = 7.7, 1.1 Hz, 1H), 3.31 (m, 2H), 3.17 (t, *J* = 7.2 Hz, 2H), 3.05 (m, 2H), 2.90 (t, *J* = 4.6 Hz, 4H), 2.38 (m, 1H), 2.20 (t, *J* = 7.9 Hz, 2H), 1.92 (m, 3H), 1.59 (m, 6H), 1.50 (m, 2H), 1.42 (m, 1H), 1.32 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z* 546.

10

Example 10

(±)-(2-Pyrrolidin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **31**, was synthesized according to the following procedure.




15

The title compound **31** was prepared by the procedure described in Example 7, substituting pyrrolidine for morpholine. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.07 (m, 1H), 7.47 (d, *J* = 1.7 Hz, 1H), 7.23-7.32 (m, 2H), 7.16 (dd, *J* = 7.5, 1.4 Hz, 1H), 6.97 (d, *J* = 8.1 Hz, 1H), 6.75-6.83 (m, 2H), 3.16 (t, *J* = 4.4 Hz, 4H), 3.30 (m, 2H), 3.17 (t, *J* = 7.2 Hz, 1H), 3.04 (m, 2H), 2.96 (t, *J* = 4.6 Hz, 4H), 2.29 (m, 1H), 2.20 (t, *J* = 7.1 Hz, 2H), 3.03 (m, 2H), 2.28 (m, 1H), 2.19 (t, *J* = 8.0 Hz, 2H), 1.82-1.94 (m, 4H), 1.76-1.80 (m, 4H), 1.55-1.62 (m, 2H), 1.35 (m, 1H), 1.23 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z* 532.

20

Example 11


(±)-(3-Morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-  
 5 2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **32**, was synthesized according to the following procedure.



The title compound **32** was prepared by the procedures described in Examples  
 1 and 7 substituting 3-bromobenzenethiol for 2-bromobenzenethiol. <sup>1</sup>H NMR (300  
 MHz, DMSO-d<sub>6</sub>) δ 8.09 (t, *J* = 5.6 Hz, 1H), 7.54 (d, *J* = 1.7 Hz, 1H), 7.34 (dd, *J* =  
 8.3, 1.9 Hz, 1H), 7.24 (m, 1H), 7.19 (d, *J* = 8.5 Hz, 1H), 6.94 (m, 2H), 6.67 (m, 1H),  
 3.71 (t, *J* = 4.9 Hz, 4H), 3.16 (t, *J* = 7.1 Hz, 2H), 3.30 (m, 2H), 3.10 (t, *J* = 4.9 Hz,  
 15 4H), 3.05 (m, 2H), 2.34 (m, 1H), 2.19 (t, *J* = 8.0 Hz, 2H), 1.89 (m, 3H), 1.58 (m, 2H);  
 MS (APCI) (M+H)<sup>+</sup> at *m/z* 548.

Example 12

(±)-(2-Morpholin-1-ylphenyl) [2,3-dichloro-4-(*trans*-(2-carboxycycloprop-1-  
 20 yl)phenyl)sulfide, **33**, was synthesized according to the following procedure.






The title compound **33** was prepared first by the procedure described in Example 2, substituting 2-bromobenzenethiol for 2-isopropylbenzenethiol. The resultant aldehyde was converted to the corresponding cyclopropanecarboxylic acid according to Example 1, steps 1B and 1C. The title compound was then prepared following Example 7. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 7.34 (dt, *J* = 7.8, 1.7 Hz, 1H), 7.22 (dd, *J* = 7.8, 1.4 Hz, 1H), 6.97-7.12 (m, 4H), 3.58 (t, *J* = 4.4 Hz, 4H), 2.95 (t, *J* = 4.4 Hz, 4H), 2.58 (m, 1H), 1.74 (m, 1H), 1.45 (t, *J* = 6.3, 2H); MS (APCI) (M)<sup>+</sup> at m/z 424.

### 10 Example 13

(±)-(2-Morpholin-1-ylphenyl) [2-trifluoromethyl-2-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-propyl-N-methylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **34**, was synthesized according to the following procedure.



Sodium hydride (60% dispersion, 0.0096 g, 0.241 mmol) was added to a solution of compound **28** (0.1200 g, 0.219 mmol) in DMF (0.55 mL). After 15 minutes, iodomethane (0.026 mL, 0.42 mmol) was added. After four hours, the reaction was diluted with Et<sub>2</sub>O and washed with sat. NH<sub>4</sub>Cl, H<sub>2</sub>O (2x), and brine. The organic layer was dried Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. Purification by preparative HPLC provided the title compound **34** (0.0922 g, 75%). <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 7.45 (d, *J* = 1.5 Hz, 1H), 7.16-7.37 (m, 3H), 7.09 (dd, *J* = 8.1, 1.1


Hz, 1H), 6.98 (dt,  $J = 7.3, 1.3$  Hz, 3H), 6.83-6.91 (m, 1H), 3.76 (t,  $J = 4.4$  Hz, 4H), 3.32-3.51 (m, 6H), 3.17 (s, 2H), 3.06 (t,  $J = 4.4$  Hz, 4H), 3.00 (s, 1H), 2.45-2.59 (m, 3H), 1.99-2.25 (m, 3H), 1.65-1.94 (m, 3H), 1.31-1.38 (m, 1H); MS (APCI)  $(M+H)^+$  at  $m/z$  562.

5

10

#### Example 14

15         $(\pm)$ -(2-Bromophenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, **35**, was synthesized according to the following procedure.




20        The title compound **35** was prepared by the procedure described in Example 2, substituting 2-bromobenzenethiol for 2-isopropylbenzenethiol. The resultant aldehyde was then converted to the title compound by following the procedures of Example 1, steps 1B, 1C, and 1D.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.56 (dd,  $J = 8.4, 1.3$  Hz, 1H), 7.18 (dt,  $J = 7.2, 1.4$  Hz, 1H), 7.08 (m, 2H), 7.03 (br s, 1H), 6.81 (d,  $J = 8.5$  Hz, 1H), 6.77 (d,  $J = 8.0$  Hz, 1H), 3.21-3.34 (m, 5H), 3.11 (m, 1H), 2.60 (m, 1H), 2.32 (t,  $J = 8.0$  Hz, 2H), 1.98 (m, 2H), 1.62 (t,  $J = 5.9$  Hz, 2H), 1.52 (m, 2H), 1.12 (m, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  176.0, 171.4, 139.5, 135.2, 134.7, 133.9, 133.6, 133.3, 132.95, 129.2, 129.1, 128.3, 127.3, 125.5, 47.5, 39.6, 35.7, 30.9, 26.5, 25.4, 23.9, 17.9, 14.2; MS (APCI)  $(M+H)^+$  at  $m/z$  543; Anal. Calc'd for

$C_{23}H_{23}N_2O_2SCl_2Br \cdot 0.6 H_2O$ : C, 49.94; H, 4.41; N, 5.06. Found: C, 49.94; H, 4.04; N, 4.85.

### Example 15

(±)-(2-Bromophenyl) [2,3-dichloro-4-(*trans*-(2-carboxycycloprop-1-yl)phenyl)sulfide, **36**, was synthesized according to the following procedure.




**36**

The title compound **36** was prepared by the procedure described in Example 2, substituting 2-bromobenzenethiol for 2-isopropylbenzenethiol. The resultant aldehyde was then converted to the title compound by following the procedure of Example 1, steps 1B and 1C.  $^1H$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  7.79 (dd,  $J = 8.1, 1.3$  Hz, 1H), 7.42 (dt,  $J = 7.6, 1.7$  Hz, 1H), 7.34 (dt,  $J = 7.6, 2.1$  Hz, 1H), 7.25 (dd,  $J = 7.6, 1.7$ , 1H), 7.14 (d,  $J = 8.5$  Hz, 1H), 6.94 (d,  $J = 8.1$  Hz, 1H), 3.36 (br s, 1H), 2.58 (m, 1H), 1.79 (m, 1H), 1.46 (m, 2H);  $^{13}C$  NMR (75 MHz,  $CDCl_3$ )  $\delta$  173.6, 138.9, 133.8, 133.7, 133.2, 133.1, 133.0, 131.7, 130.2, 129.4, 129.1, 126.3, 125.6, 24.05, 22.94, 15.12 MS (APCI)  $(M+H)^+$  at  $m/z$  453; Anal. Calc'd for  $C_{16}H_{11}O_2BrCl_2S \cdot 0.05 H_2O$ : C, 45.86; H, 2.67; N, .00. Found: C, 45.8; H, 2.49; N, 0.0.

### Example 16


(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-carboxyethylamino) carbonyl)cycloprop-1-yl)phenyl]sulfide, **37**, was synthesized according to the following procedure.



The title compound **37** was prepared by the procedures described in Example 2, substituting β-alanine hydrochloride for glycine methyl ester hydrochloride. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.42 (m, 3H); 7.21 (m, 1H), 6.73 (d, *J* = 8.3 Hz, 1H), 6.40 (d, *J* = 8.3, 1H), 6.27 (t, *J* = 6.1, 1H), 3.59 (m, 2H), 3.46 (m, 1H), 2.64 (m, 3H), 1.61 (m, 1H), 1.40 (m, 1H), 1.23 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 454, 452 Anal. Calc'd for C<sub>22</sub>H<sub>23</sub>NO<sub>3</sub>SCl<sub>2</sub> · 0.5 H<sub>2</sub>O: C, 57.27; H, 5.24; N, 3.04. Found: C, 57.22; H, 5.12; N, 2.84.

#### 15 Example 17

(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(3-carboxypropylamino) carbonyl)cycloprop-1-yl)phenyl]sulfide, **38**, was synthesized according to the following procedure.



The title compound **38** was prepared by the procedure described in Example 2, substituting ethyl 4-amino butyrate for glycine methyl ester hydrochloride. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.41 (m, 3H), 7.22 (m, 1H), 6.74 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* =


8.5, 1H), 5.96 (t,  $J = 6.0$ , 1H), 3.41 (m, 3H), 2.63 (m, 1H), 2.43 (t,  $J = 7.0$  Hz, 2H), 1.88 (m, 2H), 1.61 (m, 1H), 1.39 (m, 1H), 1.22 (m, 1H), 1.18 (d,  $J = 6.8$  Hz, 6H), MS (APCI) ( $M$ )<sup>+</sup> at  $m/z$  468, 466 Anal. Calc'd for  $C_{23}H_{25}NO_3SCl_2 \cdot 0.1 H_2O \cdot 0.05 CH_3CN$ : C, 59.00; H, 5.43; N, 3.13. Found: C, 58.98; H, 5.49; N, 3.13.

5

Example 18

(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, **39**, was synthesized according to the following procedure.

10




The title compound **39** was prepared by the procedure described in Example 3 substituting ethyl isonipecotate for ethyl nipecotate. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.44 (m, 3H), 7.22 (m, 1H), 6.76 (d,  $J = 8.5$  Hz, 1H), 6.40 (d,  $J = 8.5$ , 1H), 4.45 (m, 1H), 4.03 (m, 1H), 3.47 (m, 1H), 3.23 (m, 1H), 2.91 (m, 1H), 2.61 (m, 2H), 1.95 (m, 3H), 1.64-1.82 (m, 3H), 1.22 (m, 1H), 1.18 (d,  $J = 6.8$  Hz, 6H), MS (APCI) ( $M$ )<sup>+</sup> at  $m/z$  494, 492 Anal. Calc'd for  $C_{25}H_{27}NO_3SCl_2 \cdot 0.65 H_2O \cdot 0.1 TFA$ : C, 58.71; H, 5.55; N, 2.72. Found: C, 58.7; H, 5.56; N, 2.49.

20

Example 19

(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, **40**, was synthesized according to the following procedure.


25



The title compound **40** was prepared by the procedure described in Example 3, substituting ethyl pipecolate for ethyl nipecotate. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.44 (m, 3H), 7.22 (m, 1H), 6.77 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 5.28 (m, 1H), 3.98 (m, 1H), 3.47 (m, 1H), 3.31 (m, 1H), 2.58 (m, 1H), 2.28 (m, 1H), 1.56-1.89 (m, 7H), 1.26 (m, 1H), 1.18 (dd, *J* = 6.8, 1.0 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 494, 492 Anal. Calc'd for C<sub>25</sub>H<sub>27</sub>NO<sub>3</sub>SCl<sub>2</sub> · 0.3 H<sub>2</sub>O · 0.1 TFA: C, 59.43; H, 5.48; N, 2.75. Found: C, 59.41; H, 5.48; N, 2.56.

#### Example 20


(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(morpholin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, **41**, was synthesized according to the following procedure.



The title compound **41** was prepared by the procedure described in Example 3, substituting morpholine for ethyl nipectotate and omitting the final hydrolysis protocol. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.43 (m, 3H), 7.22 (m, 1H), 6.77 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 3.53-3.82 (m, 8H), 3.47 (m, 1H), 2.67 (m, 1H), 1.64 (m, 2H), 1.23 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 452, 450.

5 Example 21


(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(4-acetylpiperazin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, **42**, was synthesized according to the following procedure.

10 **42**

The title compound **42** was prepared by the procedure described in Example 3, substituting *N*-acetylpiperazine for ethyl nipectotate and omitting the final hydrolysis  
15 protocol. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.44 (m, 3H), 7.22 (m, 1H), 6.77 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 3.42-3.86 (m, 9H), 2.64 (m, 1H), 2.14 (s, 3H), 1.71 (m, 2H), 1.28 (m, 1H), 1.18 (d, *J* = 6.6 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 493, 491.

20 Example 22

(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, **43**, was synthesized according to the following procedure.


25 **43**

The title compound **43** was prepared by the procedure described in Example 3, substituting 3-aminopropyl-2-pyrrolidinone for ethyl nipectotate and omitting the

final hydrolysis protocol.  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  7.43 (m, 3H), 7.22 (m, 1H), 7.05 (t,  $J = 6.8$ , 1H), 6.72 (d,  $J = 8.5$  Hz, 1H), 6.40 (d,  $J = 8.5$ , 1H), 3.28-3.50 (m, 6H), 3.28 (m, 1H), 2.67 (m, 1H), 2.41 (t,  $J = 8.1$  Hz, 2H), 2.07 (m, 2H), 1.70 (m, 2H), 1.55 (m, 2H), 1.18 (d,  $J = 6.8$  Hz, 6H), 1.14 (m, 1H), MS (APCI) ( $\text{M}^+$ ) at  $m/z$  507, 505.

### Example 23

( $\pm$ )-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(pyrrolidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, **44**, was synthesized according to the following procedure.




The title compound **44** was prepared by the procedure described in Example 3, substituting pyrrolidine for ethyl nipectotatate and omitting the final hydrolysis protocol.  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  7.43 (m, 3H), 7.22 (m, 1H), 6.77 (d,  $J = 8.5$  Hz, 1H), 6.40 (d,  $J = 8.5$ , 1H), 3.41-3.68 (m, 5H), 2.62 (m, 1H), 1.92 (m, 4H), 1.67 (m, 2H), 1.18 (d,  $J = 6.8$  Hz, 7H), MS (APCI) ( $\text{M}^+$ ) at  $m/z$  436, 434.

### Example 24

( $\pm$ )-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-2-(cyclobutylaminocarbonyl)cycloprop-1-yl)phenyl]sulfide, **45**, was synthesized according to the following procedure.






The title compound **45** was prepared by the procedure described in Example 3 substituting cyclobutylamine for ethyl nipectotate and omitting the final hydrolysis protocol. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.43 (m, 3H), 7.22 (m, 1H), 6.72 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 5.77 (d, *J* = 8.1, 1H), 4.48 (m, 1H), 3.46 (m, 1H), 2.62 (m, 1H), 2.36 (m, 2H), 1.86 (m, 2H), 1.71 (m, 2H), 1.55 (m, 1H), 1.34 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 436, 434.

10

#### Example 25

(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(azetidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, **46**, was synthesized according to the following procedure.

15




The title compound **46** was prepared by the procedure described in Example 3 substituting azetidine for ethyl nipectotate and omitting the final hydrolysis protocol. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.43 (m, 2H), 7.22 (m, 2H), 6.75 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 4.00-4.30 (m, 4H), 3.47 (m, 1H), 2.58 (m, 1H), 2.32 (m, 2H), 1.60 (m, 2H), 1.45 (m, 1H), 1.19 (d, *J* = 6.8 Hz, 6H), MS (APCI) (M)<sup>+</sup> at *m/z* 422, 420.

25

**Example 26**


(±)-(2-Isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-morpholin-1-ylethyl)carbonyl) cycloprop-1-yl)phenyl]sulfide, **47**, was synthesized according to the following procedure.



The title compound **47** was prepared by the procedure described in Example 3 substituting 4-(2-aminoethyl)morpholine for ethyl nipectotatate and omitting the final hydrolysis protocol. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.43 (m, 3H), 7.22 (m, 1H), 7.19 (m, 1H), 6.74 (d, *J* = 8.5 Hz, 1H), 6.40 (d, *J* = 8.5, 1H), 3.76 (m, 4H), 3.46 (m, 3H), 2.53 (m, 7H), 1.62 (m, 1H), 1.49 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 7H), MS (APCI) (M)<sup>+</sup> at *m/z* 495, 493.

**Example 27**

(2-(3-Carboxypiperidin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide; Isomer #1, **48A**, was synthesized according to the following procedure.



The title compound **48A** was prepared by the procedure described in Example 7, substituting compound **19a** for compound **19** and ethyl nipecotatate for morpholine.

The crude products were dissolved in THF ( 1.0 mL) and EtOH (1.0 mL) and treated with 2N NaOH until ester hydrolysis was complete by TLC. The solution was poured into 2N HCl and extracted with EtOAc (2x). The combined organic layers were rinsed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by preparative HPLC. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.20-7.52 (m, 5H), 6.79-6.91 (m, 2H), 4.00 (br s, 2H), 2.90-3.65 (m, 10H), 2.50 (m, 4H), 2.13 (m, 3H), 1.50-2.02 (m, 6H), 1.45 (m, 1H), 1.34 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at m/z 590.

#### Example 28

(2-(3-Carboxypiperidin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide; Isomer #2, **48B**, was synthesized according to the following procedure. The title compound **48B** was prepared by the procedure described in Example 7, substituting compound **19B** for compound **19** and ethyl nipecotate for morpholine. The crude products were dissolved in THF (1.0 mL) and EtOH (1.0 mL) and treated with 2N NaOH until ester hydrolysis was complete by TLC. The solution was poured into 2N HCl and extracted with EtOAc (2x). The combined organic layers were rinsed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by preparative HPLC. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.20-7.52 (m, 5H), 6.79-6.91 (m, 2H), 4.00 (br s, 2H), 2.90-3.65 (m, 10H), 2.50 (m, 4H), 2.13 (m, 3H), 1.50-2.02 (m, 6H), 1.45 (m, 1H), 1.34 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at m/z 590; Anal. Calc'd for C<sub>30</sub>H<sub>34</sub>N<sub>3</sub>O<sub>4</sub>SF<sub>3</sub>· 0.4 H<sub>2</sub>O· 0.75 TFA: C, 55.44; H, 5.25; N, 6.16. Found: C, 55.42; H, 5.26; N, 6.09.

#### Example 29

(2-(Morpholin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide; Isomer #1, **28A**, was

synthesized according to the following procedure. The title compound **28A** was prepared by the procedure described in Example 7, substituting compound **19A** for compound **19**. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.45 (d, *J* = 1.8 Hz, 1H), 7.07-7.24 (m, 4H), 6.97 (dt, *J* = 7.5, 1.5 Hz, 1H), 6.84 (dd, *J* = 8.1, 1.5 Hz, 1H), 3.78 (t, *J* = 4.6 Hz, 4H), 3.42 (m, 4H), 3.17-3.37 (m, 4H), 3.05 (t, *J* = 4.4 Hz, 4H), 2.53 (m, 1H), 2.47 (m, 2H), 2.09 (m, 2H), 1.72 (m, 3H), 1.25 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z*=548; FAB HRMS *m/z* (calc'd for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub>S<sub>1</sub>F<sub>3</sub> (M+H)= 548.2195 Obs. 548.2188); Anal. Calc'd for C<sub>28</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub>SF<sub>3</sub> · 2.55 H<sub>2</sub>O: C, 56.66; H, 6.30; N, 7.08. Found: C, 56.7; H, 6.01; N, 6.72.

10

### Example 30


(2-(Morpholin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide; Isomer #2, **28B**, was synthesized by the following procedure. The title compound **28B** was prepared by the procedure described in Example 7, substituting compound **19B** for compound **19**. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.45 (d, *J* = 1.8 Hz, 1H), 7.07-7.24 (m, 4H), 6.97 (dt, *J* = 7.5, 1.5 Hz, 1H), 6.84 (dd, *J* = 8.1, 1.5 Hz, 1H), 3.78 (t, *J* = 4.6 Hz, 4H), 3.42 (m, 4H), 3.17-3.37 (m, 4H), 3.05 (t, *J* = 4.4 Hz, 4H), 2.53 (m, 1H), 2.47 (m, 2H), 2.09 (m, 2H), 1.72 (m, 3H), 1.25 (m, 1H); MS (APCI) (M+H)<sup>+</sup> at *m/z*=548; Anal. Calc'd for C<sub>28</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub>SF<sub>3</sub> · 0.55 H<sub>2</sub>O · 0.3 TFA: C, 58.05; H, 5.69; N, 7.10. Found: C, 58.1; H, 5.67; N, 7.04.

20

### Example 31

(2-(3-Carboxypiperidin-1-yl)phenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide; Isomer #2, **49B**, was synthesized according to the following procedure.

25



49

31A. Resolution of compound **35** using a Chiralpak AD HPLC column eluting with 85:15 hexane:EtOH gave baseline resolution of two enantiomers which were both >98% ee by HPLC. The earlier eluting isomer is denoted isomer #1, **35A** and the later eluting isomer is denoted isomer #2, **35B**.

31B. The title compound **49B** was prepared by the procedure described in Example 7, substituting isomer #2, **35B** for compound **19** and ethyl nipecotate for morpholine. The crude products were dissolved in THF ( 1.0 mL) and EtOH (1.0 mL) and treated with 2N NaOH until ester hydrolysis was complete by TLC. The solution was poured into 2N HCl and extracted with EtOAc (2x). The combined organic layers were rinsed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by preparative HPLC. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.55 (m, 1H), 7.40 (m, 1H), 7.28 (m, 2H), 6.81 (d, *J* = 8.5 Hz, 1H), 6.60 (s, 1H), 6.57 (d, *J* = 8.5 Hz, 1H), 3.00-3.60 (m, 8H), 2.45-2.93 (m, 5H), 1.25-2.17 (m, 12H), MS (APCI) (M)<sup>+</sup> at *m/z* 590; Anal. Calc'd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>4</sub>SCl<sub>2</sub>· 0.25 H<sub>2</sub>O· 2.05 TFA: C, 47.97; H, 4.32; N, 5.07. Found: C, 47.96; H, 4.33; N, 5.08.

### Example 32


(2-(3-Carboxypiperidin-1-yl)phenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide; Isomer #1, **49A**, was synthesized according to the following procedure.

32A. Isomer #1, **35A**, was also isolated from the procedure described in Example 31, step A.

32B. The title compound **49A** was prepared by the procedure described in Example 7, substituting compound **35A** for compound **19** and ethyl nipecotate for morpholine. The crude products were dissolved in THF ( 1.0 mL) and EtOH (1.0 mL) and treated with 2N NaOH until ester hydrolysis was complete by TLC. The solution was poured into 2N HCl and extracted with EtOAc (2x). The combined organic layers were rinsed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by preparative HPLC. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.78 (m, 1H), 7.64 (m, 1H), 7.49 (m, 1H), 7.42 (m, 1H), 7.24 (m, 1H), 6.81 (br s, 1H), 6.77 (m, 1H), 6.40 (m, 1H), 3.70 (m, 1H), 3.48 (m, 5H), 3.30 (m, 1H), 3.18 (m, 1H); 2.62-3.08 (m, 4H), 2.52 (m, 3H), 2.11 (m, 3H), 1.55-1.90 (m, 5H), 1.25-1.45 (m, 2H); MS (APCI) (M)<sup>+</sup> at m/z 590; Anal. Calc'd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>4</sub>SCl<sub>2</sub> · 0.7 H<sub>2</sub>O · 2.15 TFA: C, 47.15; H, 4.34; N, 4.95. Found: C, 47.11; H, 4.25; N, 5.3.

### Example 33


(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(carboxymethylamino)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #1, **50A**, was synthesized according to the following procedure.



**50**

33A. First, ( $\pm$ )-(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-ethoxycarbonyl)cycloprop-1-yl]phenyl]sulfide, **51**, was synthesized according to the following procedure.

5



Compound **51** was prepared according to the procedures of Example 2A and  
 10 2B, substituting 2-methoxythiophenol for 2-isopropylthiophenol and eliminating the final hydrolysis procedure.

33B. Then (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-ethoxycarbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer # 1, **51A**, was prepared as follows. Resolution of compound **51** using a Chiralcel OD HPLC column eluting with 95:5 hexane:*i*-  
 15 PrOH gave baseline resolution of two enantiomers which were both >98% ee by HPLC. The earlier eluting isomer is denoted isomer #1 (**51A**) and the later eluting isomer is denoted isomer #2 (**51B**).


33C. The title compound **50A** was prepared from compound **51A** using the hydrolysis procedure described in Example 1C followed by the coupling procedure  
 20 described in Example 3, substituting glycine methyl ester hydrochloride for ethyl nipecotate.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.77 (d,  $J = 9$  Hz, 1H), 6.61 (d,  $J = 9$  Hz, 1H), 6.33 (m, 1H), 4.14 (m, 2H), 3.82 (s, 3H), 2.67 (m, 1H), 1.62 (m, 1H), 1.54 (m, 1H), 1.27 (m, 1H); MS (APCI) ( $\text{M}$ ) $^+$  at  $m/z$  426; Anal. Calcd for  $\text{C}_{19}\text{H}_{17}\text{NO}_4\text{SCl}_2 \cdot 0.4 \text{ H}_2\text{O} \cdot 0.1 \text{ TFA}$ : C, 51.83; H, 4.06; N, 3.15. Found:

C, 51.82; H, 4.05; N, 3.06.

5

Example 34

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxyethylamino)carbonyl)  
10 cycloprop-1-yl)phenyl]sulfide, Isomer #1, **52A**, was synthesized according to the following procedure.




**52**

15 The title compound **52A** was prepared by the procedures described in Example 33, substituting  $\beta$ -alanine ethyl ester for glycine methyl ester hydrochloride.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) 7.45-7.30 (m, 2H), 6.97 (m, 2H), 6.77 (d,  $J=9$  Hz, 1H), 6.60 (d,  $J=9$  Hz, 1H), 6.32 (m, 1H), 3.82 (s, 3H), 3.61 (m, 2H), 2.65 (m, 3H), 1.62 (m, 1H), 1.42 (m, 1H), 1.22 (m, 1H); MS (APCI) ( $\text{M}$ ) $^+$  at  $m/z$  440; Anal. Calc'd for   
20  $\text{C}_{29}\text{H}_{33}\text{N}_3\text{O}_4\text{SCl}_2 \cdot 0.25 \text{H}_2\text{O} \cdot 2.05 \text{TFA}$ : C, 47.97; H, 4.32; N, 5.07. Found: C, 47.96; H, 4.33; N, 5.08.

Example 35

25 (2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypropylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, Isomer #1, **53A**, was synthesized according to the following procedure.



**53**


The title compound **53A** was prepared by the procedure described in Example

5 33, substituting ethyl 4-aminobutyrate for glycine methyl ester hydrochloride. <sup>1</sup>H  
NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.78 (d, J=9 Hz, 1H), 6.61  
(d, J=9 Hz, 1H), 6.00 (m, 1H), 3.83 (s, 3H), 3.41 (m, 2H), 2.64 (m, 1H), 2.43 (t, J=8  
Hz, 2H), 1.88 (m, 2H), 1.62 (m, 1H), 1.41 (m, 1H), 1.23 (m, 1H); MS (APCI) (M)<sup>+</sup> at  
m/z 454; Anal. Calc'd for C<sub>23</sub>H<sub>23</sub>NO<sub>4</sub>SCl<sub>2</sub> · 0.7 H<sub>2</sub>O · 0.9 TFA: C, 50.01; H, 4.28;  
10 N, 2.35. Found: C, 50; H, 4.3; N, 2.46.

15

### Example 36

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(4-carboxypiperidin-1-  
20 yl)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #1, **54A**, was synthesized  
according to the following procedure.

**54**

25

The title compound **54A** was prepared by the procedure described in Example


33, substituting ethyl isonipecotate for glycine methyl ester hydrochloride. <sup>1</sup>H NMR

(CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.79 (d, J=9 Hz, 1H), 6.62 (d, J=9 Hz, 1H), 4.46 (m, 1H), 4.05 (m, 1H), 3.83 (s, 3H), 3.25 (m, 1H), 2.96 (m, 1H), 2.62 (m, 2H), 2.00 (m, 2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.24 (m, 1H); MS (APCI) (M)<sup>+</sup> at m/z 482, 480; Anal. Calc'd for C<sub>23</sub>H<sub>23</sub>NO<sub>4</sub>SCl<sub>2</sub>· 0.7 H<sub>2</sub>O· 0.9 TFA: C, 50.01; H, 4.28; N, 2.35. Found: C, 50; H, 4.3; N, 2.46.

### 10 Example 37

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #1, **55A**, was synthesized according to the following procedure.

15




**55**

20 The title compound **55A** was prepared by the procedure described in Example 33, substituting ethyl nipecotate for glycine methyl ester hydrochloride. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.79 (d, J=9 Hz, 1H), 6.62 (d, J=9 Hz, 1H), 4.51 (m, 1H), 4.07 (m, 1H), 3.83 (s, 3H), 3.50-3.00 (m, 2H), 2.62 (m, 2H), 2.20-1.40 (m, 6H), 1.24 (m, 1H); MS (APCI) (M)<sup>+</sup> at m/z 482, 480; Anal. Calc'd for C<sub>23</sub>H<sub>23</sub>NO<sub>4</sub>SCl<sub>2</sub>· 0.7 H<sub>2</sub>O· 0.9 TFA: C, 50.01; H, 4.28; N, 2.35. Found: C, 50; H, 4.3; N, 2.46.

### Example 38

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #1, **56A**, was synthesized according to the following procedure.

**56**

The title compound **56A** was prepared by the procedures described in Example 33, substituting ethyl pipercolinate for glycine methyl ester hydrochloride. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.99 (m, 2H), 6.81 (d, J=9 Hz, 1H), 6.61 (d, J=9 Hz, 1H), 5.38 (m, 1H), 4.04 (m, 1H), 3.84 (s, 3H), 3.50 (s, 1H), 3.31 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.89 (m, 1H), 1.72 (m, 4H), 1.62 (m, 2H), 1.31 (m, 1H); MS (APCI) (M)<sup>+</sup> at m/z 482, 480; Anal. Calc'd for C<sub>23</sub>H<sub>23</sub>NO<sub>4</sub>SCl<sub>2</sub>· 1.5 H<sub>2</sub>O· 1.25 TFA: C, 47.12; H, 4.23; N, 2.15. Found: C, 47.11; H, 4.16; N, 2.49.

#### Example 39

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(carboxymethylamino)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **50B**, was synthesized according to the following procedure.

39A. First, (2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-ethoxycarbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **51B**, was also isolated from the procedure described in Example 33B.

39B. The title compound **50B** was prepared from compound **51B** using the hydrolysis procedure described in Example 1, step C followed by the coupling procedure described in Example 3, substituting glycine methyl ester hydrochloride for ethyl nipecotate. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.77 (d, *J* = 9 Hz, 1H), 6.61 (d, *J* = 9 Hz, 1H), 6.33 (m, 1H), 4.14 (m, 2H), 3.82 (s, 3H), 2.67 (m, 1H), 1.62 (m, 1H), 1.54 (m, 1H), 1.27 (m, 1H). *m/e* (ESI) 424, 426 (MH<sup>+</sup>)  
Anal. Calc'd for C<sub>19</sub>H<sub>17</sub>Cl<sub>2</sub>NO<sub>4</sub>S· 0.40 H<sub>2</sub>O: C, 52.64; H, 4.14; N, 3.23. Found: C, 52.59; H, 4.01; N, 3.40.

#### 10 Example 40

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxyethylamino)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **52B**, was synthesized according to the following procedure.

15 The title compound **52B** was prepared by the procedures described in Example 39, substituting β-alanine ethyl ester for glycine methyl ester hydrochloride. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.97 (m, 2H), 6.77 (d, *J*=9 Hz, 1H), 6.60 (d, *J*=9 Hz, 1H), 6.32 (m, 1H), 3.82 (s, 3H), 3.61 (m, 2H), 2.65 (m, 3H), 1.62 (m, 1H), 1.42 (m, 1H), 1.22 (m, 1H). *m/e* (ESI) 438, 440 (MH<sup>+</sup>) Anal. Calc'd for  
20 C<sub>20</sub>H<sub>19</sub>Cl<sub>2</sub>NO<sub>4</sub>S· 0.45 H<sub>2</sub>O: C, 53.57; H, 4.47; N, 3.12. Found: C, 53.53; H, 4.42; N, 3.00

#### Example 41

25 (2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypropylamino)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **53B**, was synthesized according to the following procedure.

The title compound **53B** was prepared by the procedures described in Example 39, substituting ethyl 4-aminobutyrate for glycine methyl ester

hydrochloride.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.78 (d,  $J=9$  Hz, 1H), 6.61 (d,  $J=9$  Hz, 1H), 6.00 (m, 1H), 3.83 (s, 3H), 3.41 (m, 2H), 2.64 (m, 1H), 2.43 (t,  $J=8$  Hz, 2H), 1.88 (m, 2H), 1.62 (m, 1H), 1.41 (m, 1H), 1.23 (m, 1H). m/e (ESI) 452, 454 ( $\text{MH}^+$ ) Anal. Calc'd for  $\text{C}_{21}\text{H}_{21}\text{Cl}_2\text{NO}_4\text{S} \cdot 0.55 \text{H}_2\text{O}$ : C, 54.33; H, 4.80; N, 3.02. Found: C, 54.31; H, 4.65; N, 2.76.

#### Example 42

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **54B**, was synthesized according to the following procedure.

The title compound **54B** was prepared by the procedure described in Example 39, substituting ethyl isonipecotate for glycine methyl ester hydrochloride.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.79 (d,  $J=9$  Hz, 1H), 6.62 (d,  $J=9$  Hz, 1H), 4.46 (m, 1H), 4.05 (m, 1H), 3.83 (s, 3H), 3.25 (m, 1H), 2.96 (m, 1H), 2.62 (m, 2H), 2.00 (m, 2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.24 (m, 1H). m/e (ESI) 478, 480 ( $\text{MH}^+$ ) Anal. Calc'd for  $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{NO}_4\text{S}$ : C, 57.50; H, 4.83; N, 2.92. Found: C, 57.33; H, 4.82; N, 2.64.

Example 43

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **55B**, was synthesized according to the following procedure.

The title compound **55B** was prepared by the procedure described in Example 39, substituting ethyl nipecotate for glycine methyl ester hydrochloride. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.98 (m, 2H), 6.79 (d, J=9 Hz, 1H), 6.62 (d, J=9 Hz, 1H), 4.51 (m, 1H), 4.07 (m, 1H), 3.83 (s, 3H), 3.50-3.00 (m, 2H), 2.62 (m, 2H), 2.20-1.40 (m, 6H), 1.24 (m, 1H). m/e (ESI) 478, 480 (MH<sup>+</sup>) Anal. Calc'd for C<sub>23</sub>H<sub>23</sub>Cl<sub>2</sub>NO<sub>4</sub>S · 0.25 H<sub>2</sub>O: C, 56.97; H, 4.88; N, 2.89. Found: C, 56.91; H, 4.68; N, 2.68.


Example 44

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl]phenyl]sulfide, Isomer #2, **56B**, was synthesized according to the following procedure.

The title compound **56B** was prepared by the procedure described in Example 39, substituting ethyl pipecolate for glycine methyl ester hydrochloride. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) 7.45-7.30 (m, 2H), 6.99 (m, 2H), 6.81 (d, J=9 Hz, 1H), 6.61 (d, J=9 Hz, 1H), 5.38 (m, 1H), 4.04 (m, 1H), 3.84 (s, 3H), 3.50 (s, 1H), 3.31 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.89 (m, 1H), 1.72 (m, 4H), 1.62 (m, 2H), 1.31 (m, 1H). m/e (ESI) 478, 480 (MH<sup>+</sup>) Anal. Calc'd for C<sub>23</sub>H<sub>23</sub>Cl<sub>2</sub>NO<sub>4</sub>S · 0.40 CH<sub>2</sub>Cl<sub>2</sub>: C, 54.64; H, 4.66; N, 2.72. Found: C, 54.77; H, 4.61; N, 2.53.

Example 45

(2-Methoxyphenyl)[2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, Isomer #2, **57B**, was synthesized as follows.



The title compound **57B** was prepared by the procedure described in Example 39, substituting pyrrolidone-3-propylamine for glycine methyl ester hydrochloride, and eliminating the final hydrolysis procedure.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) 7.45-7.30 (m, 2H), 7.02 (m, 1H), 6.98 (m, 2H), 6.77 (d,  $J=9$  Hz, 1H), 6.63 (d,  $J=9$  Hz, 1H), 3.84 (s, 3H), 3.50-3.25 (m, 5H), 3.20 (m, 1H), 2.67 (m, 1H), 2.42 (t,  $J=8$  Hz, 2H), 2.08 (m, 2H), 1.71 (m, 2H), 1.58 (m, 2H), 1.17 (m, 1H).  $m/e$  (ESI) 493, 495 ( $\text{MH}^+$ ). Anal. Calc'd for  $\text{C}_{24}\text{H}_{26}\text{Cl}_2\text{N}_2\text{O}_3\text{S} \cdot 0.40 \text{ CH}_2\text{Cl}_2$ : C, 55.57; H, 5.12; N, 5.31. Found: C, 55.65; H, 5.09; N, 5.23.

Example 46

Compounds that antagonize the interaction between ICAM-1 and LFA-1 can be identified, and their activities quantitated, using both biochemical and cell-based adhesion assays. A primary biochemical assay, described below as assay 46A, was utilized to measure the ability of the present compounds to block the interaction between the integrin LFA-1 and its adhesion partner ICAM-1.

46A. ICAM-1 / LFA-1 Biochemical Interaction Assay

In the biochemical assay, 100 mL of anti-LFA-1 antibody (ICOS Corporation) at a concentration of 5 mg/ml in Dulbecco's phosphate-buffered saline

(D-PBS) is used to coat wells of a 96-well microtiter plate overnight at 4°C. The wells are then washed twice with wash buffer (D-PBS w/o Ca<sup>++</sup> or Mg<sup>++</sup>, 0.05% Tween 20) and blocked by addition of 200 mL of D-PBS, 5% fish skin gelatin. Recombinant LFA-1 (100 mL of 0.7 mg/ml, ICOS Corporation) in D-PBS is then

5 added to each well. Incubation continues for 1 hour at room temperature and the wells are washed twice with wash buffer. Serial dilutions of compounds being assayed as ICAM-1/LFA-1 antagonists, prepared as 10 mM stock solutions in dimethyl sulfoxide (DMSO), are diluted in D-PBS, 2mM MgCl<sub>2</sub>, 1% fish skin gelatin and 50 mL of each dilution added to duplicate wells. This is followed by addition of

10 50 mL of 0.8 mg/ml biotinylated recombinant ICAM-1/Ig (ICOS Corporation) to the wells and the plates are incubated at room temperature for 1 hour. The wells are then washed twice with wash buffer and 100 mL of Europium-labeled Streptavidin (Wallac Oy) diluted 1:100 in Delfia assay buffer (Wallac Oy) are added to the wells. Incubation proceeds for 1 hour at room temperature. The wells are washed eight

15 times with wash buffer and 100 µL of enhancement solution (Wallac Oy, cat. No. 1244-105) are added to each well. Incubation proceeds for 5 minutes with constant mixing. Time-resolved fluorimetry measurements are made using the Victor 1420 Multilabel Counter (Wallac Oy) and the percent inhibition of each candidate compound is calculated using the following equation:

$$20 \quad \% \text{ inhibition} = 100 \times \left\{ 1 - \frac{\text{average OD w/ compound minus background}}{\text{average OD w/o compound minus background}} \right\}$$

where "background" refers to wells that are not coated with anti-LFA-1 antibody.

Compounds of the present invention exhibit inhibitory activity in the above assay as illustrated in Table 1.

Table 1



Compound of Example	% inhibition
1	92% @ 4μM
2	95% @ 2μM
3	96% @ 2μM
4	81% @ 2μM
5	94% @ 2μM
6	90% @ 4μM
7	93% @ 4μM
8	94% @ 4μM
9	95% @ 4μM
10	94% @ 4μM
11	44% @ 4μM
12	91% @ 4μM
13	93% @ 4μM
14	92% @ 4μM
15	88% @ 4μM
16	96% @ 2μM
17	95% @ 2μM
18	93% @ 2μM
19	96% @ 2μM
20	96% @ 2μM
21	94% @ 2μM

22	96% @ 2 $\mu$ M
23	94% @ 2 $\mu$ M
24	94% @ 2 $\mu$ M
25	95% @ 2 $\mu$ M
26	95% @ 2 $\mu$ M
27	93% @ 2 $\mu$ M
28	97% @ 2 $\mu$ M
29	94% @ 2 $\mu$ M
30	97% @ 2 $\mu$ M
31	95% @ 4 $\mu$ M
32	96% @ 4 $\mu$ M
33	93% @ 4 $\mu$ M
34	95% @ 4 $\mu$ M
35	95% @ 4 $\mu$ M
36	95% @ 4 $\mu$ M
38	93% @ 4 $\mu$ M
39	94% @ 4 $\mu$ M
40	96% @ 4 $\mu$ M
41	96% @ 4 $\mu$ M
42	96% @ 4 $\mu$ M
43	96% @ 4 $\mu$ M
45	96% @ 4 $\mu$ M

Biologically relevant activity of the compounds in this invention was confirmed using a cell-based adhesion assay, (described below as assay 46B) which measured the ability of the present compounds to block the adherence of JY-8 cells (a human EBV-transformed B cell line expressing LFA-1 on its surface) to  
5 immobilized ICAM-1.

46B. ICAM-1 / JY-8 cell adhesion assay

For measurement of inhibitory activity in the cell-based adhesion assay, 96-well microtiter plates are coated with 70  $\mu$ L of recombinant ICAM-1/Ig (ICOS Corporation) at a concentration of 5  $\mu$ g/mL in D-PBS w/o  $\text{Ca}^{++}$  or  $\text{Mg}^{++}$  overnight at  
10 4°C. The wells are then washed twice with D-PBS and blocked by addition of 200  $\mu$ L of D-PBS, 5% fish skin gelatin by incubation for 1 hour at room temperature. Fluorescent tagged JY-8 cells (a human EBV-transformed B cell line expressing LFA-1 on its surface; 50  $\mu$ L at  $2 \times 10^6$  cells/ml in RPMI 1640 (standard cell culture medium) /1% fetal bovine serum) are added to the wells. For fluorescent labeling of  
15 JY-8 cells,  $5 \times 10^6$  cells washed once in RPMI 1640 are resuspended in 1 mL of RPMI 1640 containing 2  $\mu$ M Calcein AM (MolecularProbes), are incubated at 37°C for 30 minutes and washed once with RPMI-1640/ 1% fetal bovine serum. Dilutions of compounds to be assayed for ICAM-1/LFA-1 antagonistic activity are prepared in RPMI-1640/ 1% fetal bovine serum from 10mM stock solutions in  
20 DMSO and 50  $\mu$ L are added to duplicate wells. Microtiter plates are incubated for 45 minutes at room temperature and the wells are washed gently once with RPMI-1640/ 1% fetal bovine serum. Fluorescent intensity is measured in a fluorescent plate reader with an excitation wavelength at 485 nM and an emission wavelength at 530 nM. The percent inhibition of a candidate compound at a given concentration is  
25 calculated using the following equation:

$$\% \text{ inhibition} = 100 \times \left\{ 1 - \frac{\text{average OD w/ compound}}{\text{average OD w/o compound}} \right\}$$

and these concentration/inhibition data are used to generate dose response curves, from which IC<sub>50</sub> values are derived. Compounds of the present invention exhibit blocking activity in the above assay as illustrated in Table 2.

5

Table 2

Compound of Example	% inhibition @ 4μM
3	90% @ 2μM
7	84% @ 1μM
8	70% @ 4μM
9	76% @ 4μM
10	72% @ 4μM
13	86% @ 1μM
14	80% @ 1μM
16	88% @ 2μM
17	86% @ 2μM
18	84% @ 2μM
21	88% @ 2μM
22	92% @ 2μM
28	90% @ 2μM
30	89% @ 2μM
31	88% @ 2μM
32	86% @ 2μM

The ability of the compounds of this invention to treat arthritis can be demonstrated in a murine collagen-induced arthritis model according to the method of Kakimoto, et al., *Cell Immunol* 142: 326-337, 1992, in a rat collagen-induced arthritis model according to the method of Knoerzer, et al., *Toxicol Pathol* 25:13-19, 1997, in  
5 a rat adjuvant arthritis model according to the method of Halloran, et al., *Arthritis Rheum* 39: 810-819, 1996, in a rat streptococcal cell wall-induced arthritis model according to the method of Schimmer, et al., *J Immunol* 160: 1466-1477, 1998, or in a SCID-mouse human rheumatoid arthritis model according to the method of Oppenheimer-Marks et al., *J Clin Invest* 101: 1261-1272, 1998.

10 The ability of the compounds of this invention to treat Lyme arthritis can be demonstrated according to the method of Gross et al., *Science* 281, 703-706, 1998.

The ability of compounds of this invention to treat asthma can be demonstrated in a murine allergic asthma model according to the method of Wegner et al., *Science* 247:456-459, 1990, or in a murine non-allergic asthma model according  
15 to the method of Bloemen et al., *Am J Respir Crit Care Med* 153:521-529, 1996.

The ability of compounds of this invention to treat inflammatory lung injury can be demonstrated in a murine oxygen-induced lung injury model according to the method of Wegner et al., *Lung* 170:267-279, 1992, in a murine immune complex-induced lung injury model according to the method of Mulligan et al., *J Immunol*  
20 154:1350-1363, 1995, or in a murine acid-induced lung injury model according to the method of Nagase, et al., *Am J Respir Crit Care Med* 154:504-510, 1996.

The ability of compounds of this invention to treat inflammatory bowel disease can be demonstrated in a rabbit chemical-induced colitis model according to the method of Bennet et al., *J Pharmacol Exp Ther* 280:988-1000, 1997.

The ability of compounds of this invention to treat autoimmune diabetes can be demonstrated in an NOD mouse model according to the method of Hasagawa et al., *Int Immunol* 6:831-838, 1994, or in a murine streptozotocin-induced diabetes model according to the method of Herrold et al., *Cell Immunol* 157:489-500, 1994.

5       The ability of compounds of this invention to treat inflammatory liver injury can be demonstrated in a murine liver injury model according to the method of Tanaka et al., *J Immunol* 151:5088-5095, 1993.

The ability of compounds of this invention to treat inflammatory glomerular injury can be demonstrated in a rat nephrotoxic serum nephritis model according to  
10   the method of Kawasaki, et al., *J Immunol* 150:1074-1083, 1993.

The ability of compounds of this invention to treat radiation-induced enteritis can be demonstrated in a rat abdominal irradiation model according to the method of Panes et al., *Gastroenterology* 108:1761-1769, 1995.

The ability of compounds of this invention to treat radiation pneumonitis can  
15   be demonstrated in a murine pulmonary irradiation model according to the method of Hallahan et al., *Proc Natl Acad Sci U S A* 94:6432-6437, 1997.

The ability of compounds of this invention to treat reperfusion injury can be demonstrated in the isolated rat heart according to the method of Tamiya et al., *Immunopharmacology* 29(1): 53-63, 1995, or in the anesthetized dog according to the  
20   model of Hartman et al., *Cardiovasc Res* 30(1): 47-54, 1995.

The ability of compounds of this invention to treat pulmonary reperfusion injury can be demonstrated in a rat lung allograft reperfusion injury model according to the method of DeMeester et al., *Transplantation* 62(10): 1477-1485, 1996, or in a rabbit pulmonary edema model according to the method of Horgan et al., *Am J*  
25   *Physiol* 261(5): H1578-H1584, 1991.

The ability of compounds of this invention to treat stroke can be demonstrated in a rabbit cerebral embolism stroke model according the method of Bowes et al., *Exp Neurol* 119(2): 215-219, 1993, in a rat middle cerebral artery ischemia-reperfusion model according to the method of Chopp et al., *Stroke* 25(4): 869-875, 1994, or in a rabbit reversible spinal cord ischemia model according to the method of Clark et al., *Neurosurg* 75(4): 623-627, 1991.

The ability of compounds of this invention to treat peripheral artery occlusion can be demonstrated in a rat skeletal muscle ischemia / reperfusion model according to the method of Gute et al., *Mol Cell Biochem* 179: 169-187, 1998.

10       The ability of compounds of this invention to treat graft rejection can be demonstrated in a murine cardiac allograft rejection model according to the method of Isobe et al., *Science* 255: 1125-1127, 1992, in a murine thyroid gland kidney capsule model according to the method of Talento et al., *Transplantation* 55: 418-422, 1993, in a cynomolgus monkey renal allograft model according to the method of Cosimi et al., *J Immunol* 144: 4604-4612, 1990, in a rat nerve allograft model according to the method of Nakao et al., *Muscle Nerve* 18: 93-102, 1995, in a murine skin allograft model according to the method of Gorczynski and Wojcik, *J Immunol* 152 : 2011-2019, 1994, in a murine corneal allograft model according to the method of He et al., *Ophthalmol Vis Sci* 35: 3218-3225, 1994, or in a xenogeneic pancreatic islet cell  
15       transplantation model according to the method of Zeng et al., *Transplantation* 58:681-689, 1994.

The ability of compounds of this invention to treat graft-vs.-host disease (GVHD) can be demonstrated in a murine lethal GVHD model according to the method of Harning et al., *Transplantation* 52:842-845, 1991.

The ability of compounds of this invention to treat cancers can be demonstrated in a human lymphoma metastasis model (in mice) according to the method of Aoudjit et al., *J Immunol* 161:2333-2338, 1998.

All references cited are hereby incorporated by reference.

5           The present invention is illustrated by way of the foregoing description and examples. The foregoing description is intended as a non-limiting illustration, since many variations will become apparent to those skilled in the art in view thereof. It is intended that all such variations within the scope and spirit of the appended claims be embraced thereby.


10           Changes can be made in the composition, operation and arrangement of the method of the present invention described herein without departing from the concept and scope of the invention as defined in the following claims:



CLAIMS

We claim:



1. A compound of the structure




5

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, cyano, nitro, cycloalkyl and carboxaldehyde;  
with the proviso that at least one of  $R^1$  or  $R^3$  is selected from the group consisting of


10



15



20



“*cis*- cyclopropanamide”      “*trans*- cyclopropanamide”,

wherein R<sup>6</sup> and R<sup>7</sup> are each independently selected from the group consisting of hydrogen, alkyl, carboxy, hydroxyalkyl and carboxyalkyl;

5      R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, alkylaminocarbonylalkyl and dialkylaminocarbonylalkyl;

and R<sup>10</sup> and R<sup>11</sup> are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxyalkyl, carboxyalkyl,  
10      hydroxyalkyl, heterocyclyl; heterocyclylalkyl and heterocyclylamino;

wherein R<sup>10</sup> and R<sup>11</sup> may be joined to form a three to seven membered

heterocyclyl ring, said ring optionally being substituted with one or more substituents R<sup>15</sup>, each substituent R<sup>15</sup> independently selected from the group consisting of alkyl, alkoxy, alkoxyalkyl, cycloalkyl,  
15      aryl, heterocyclyl, heterocyclylcarbonyl, heterocyclylalkylaminocarbonyl, hydroxy, hydroxyalkyl, hydroxyalkoxyalkyl, carboxy, carboxyalkyl, carboxycarbonyl, carboxaldehyde, alkoxyalkyl, arylalkoxyalkyl, aminoalkyl, aminoalkanoyl, carboxamido, alkoxyalkyl, carboxamidoalkyl,  
20      cyano, tetrazolyl, alkanoyl, hydroxyalkanoyl, alkanoyloxy, alkanoylamino, alkanoyloxyalkyl, alkanoylaminoalkyl, sulfonate, alkylsulfonyl, alkylsulfonylaminocarbonyl, arylsulfonylaminocarbonyl and heterocyclylsulfonylaminocarbonyl;

and wherein A is an aryl or heterocyclyl group, said aryl or heterocyclyl group  
25      having at least one substituent R<sup>12</sup>, wherein R<sup>12</sup> is selected from the

group consisting of hydrogen, halogen, alkyl, aryl, haloalkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkyl, aminoalkyl, aminocarbonyl, alkyl(alkoxycarbonylalkyl) aminoalkyl, heterocyclyl, heterocyclylalkyl, carboxaldehyde, carboxaldehyde hydrazone, carboxamide, alkoxycarbonylalkyl, carboxy, carboxyalkyl, cycloalkoxy, carboxythioalkoxy, carboxycycloalkoxy, thioalkoxy, carboxyalkylamino, trans-cinnamyl, carboxyalkoxy, hydroxyalkylaminocarbonyl, cyano, amino, heterocyclylalkylamino, and heterocyclylalkylaminocarbonyl;

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$  and  $R^{15}$  are unsubstituted or substituted with at least one electron donating or electron withdrawing group;


or a pharmaceutically-acceptable salt, optical isomer or prodrug thereof.

2. The compound of claim 1 wherein  $R^3$  is "cis-cyclopropanamide" or "trans-cyclopropanamide";

$R^1$  and  $R^2$  are each independently selected from the group consisting of hydrogen, halogen, haloalkyl and nitro; and

$R^4$  and  $R^5$  are each independently selected from the group of hydrogen and alkyl.

3. The compound of claim 1 of the structure



wherein p is an integer of one to five;

q is an integer of one to four;

R<sup>12</sup> and R<sup>13</sup>, at each occurrence, are independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, carboxyalkoxy, carboxyalkyl and heterocyclyl; and,

R<sup>10</sup> and R<sup>11</sup> are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxycarbonylalkyl, carboxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl and heterocyclylamino;

wherein R<sup>10</sup> and R<sup>11</sup> may be joined to form a three to seven-membered

heterocyclyl ring, said ring being optionally substituted with one or more substituents R<sup>15</sup>, each substituent R<sup>15</sup> independently selected from the group consisting of alkyl, alkoxy, alkoxyalkyl, cycloalkyl, aryl, heterocyclyl, heterocyclylcarbonyl,

heterocyclylalkylaminocarbonyl, hydroxy, hydroxyalkyl,

hydroxyalkoxyalkyl, carboxy, carboxyalkyl, carboxycarbonyl,

carboxaldehyde, alkoxycarbonyl, arylalkoxycarbonyl, aminoalkyl,

aminoalkanoyl, carboxamido, alkoxycarbonylalkyl, carboxamidoalkyl,

cyano, tetrazolyl, alkanoyl, hydroxyalkanoyl, alkanoyloxy,


alkanoylamino, alkanoyloxyalkyl, alkanoylaminoalkyl, sulfonate,

alkylsulfonyl, alkylsulfonylaminocarbonyl, arylsulfonylaminocarbonyl

and heterocyclylsulfonylaminocarbonyl;

wherein  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$  and  $R^{15}$  are unsubstituted or substituted with at least one  
electron donating or electron withdrawing group;  
or a pharmaceutically acceptable salt, optical isomer or pro-drug thereof.

- 5           4. The compound of claim 3 wherein  $R^{10}$  and  $R^{11}$  are joined to form a three to  
seven membered heterocyclyl ring; said ring selected from the group  
consisting of piperidine, morpholine, piperazine, pyrrolidine and azetidine;  
p is one;  
q is one or two;  
10            $R^{13}$ , at each occurrence is selected from the group consisting of halogen and  
haloalkyl; and  
 $R^{12}$  is selected from the group consisting of halogen, alkyl, alkoxy,  
carboxyalkoxy, carboxyalkyl and heterocyclyl.



- 15           5. A compound of claim 1 of the structure

wherein the circle Q represents a three to seven membered heterocyclyl ring;

the circle T represents a five to seven membered heterocyclyl ring;

r is an integer of one to three;

s is an integer of one to five;

n is an integer of one to four;

- 5 R<sup>1</sup> and R<sup>2</sup>, are each independently selected from the group consisting of  
hydrogen, halogen and haloalkyl;  
R<sup>14</sup> and R<sup>15</sup>, at each occurrence, are independently selected from the group  
consisting of hydrogen, halogen, alkyl, alkoxy and carboxy; and  
wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>14</sup> and R<sup>15</sup> are unsubstituted or substituted with at least one  
10 electron donating or electron withdrawing group.

6. The compound of claim 5 wherein circle T represents pyrrolidine,  
n is three;  
and circle Q represents a three to seven membered heterocyclic ring selected from  
15 the group consisting of piperidine and morpholine.

7. A compound of claim 1 selected from the group consisting of (±)-(2-bromophenyl)[2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl)[2,3-dichloro-4-(*trans*-(carboxymethylamino)carbonyl) cycloprop-1-yl)phenyl)sulfide, (±)-(2-isopropylphenyl)[2,3-dichloro-4-(*trans*-(2-(3-carboxypiperidine))carbonyl) cycloprop-1-yl)phenyl)sulfide, (±)-(2-(2-carboxyethyl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-morpholin-1-yl)phenyl] [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl)sulfide, (±)-(2-25

morpholin-1-ylphenyl) [2-chloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-piperidin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-pyrrolidin-1-ylphenyl) [2-trifluoromethyl-4-  
 5 (*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(3-morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-morpholin-1-ylphenyl) [2,3-dichloro-4-(*trans*-(2-carboxycycloprop-1-yl)phenyl]sulfide, (±)-(2-morpholin-1-ylphenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-propyl-N-methylamino) carbonyl) cycloprop-1-yl)phenyl]sulfide, (  
 10 (±)-(2-bromophenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-bromophenyl) [2,3-dichloro-4-(*trans*-(2-carboxycycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-carboxyethylamino) carbonyl)cycloprop-1-yl)phenyl]sulfide, (  
 15 (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(3-carboxypropyl amino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl] sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-  
 20 (*trans*-(2-(morpholin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(4-acetylpiperazin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(pyrrolidin-1-  
 25 yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-

- (*trans*-2-(cyclobutylaminocarbonyl) cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(azetidin-1-yl)carbonyl) cycloprop-1-yl)phenyl]sulfide, (±)-(2-isopropylphenyl) [2,3-dichloro-4-(*trans*-(2-(2-morpholin-1-ylethyl)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-(3-carboxypiperidin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-(morpholin-1-yl)phenyl) [2-trifluoromethyl-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-(3-carboxypiperidin-1-yl)phenyl) [2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(carboxymethylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxyethylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypropylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(2-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl) [2,3-dichloro-4-(*trans*-2-(2-carboxyethylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypropylamino)carbonyl) cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(4-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-2-(3-carboxypiperidin-1-yl)carbonyl)cycloprop-1-yl)phenyl]sulfide, (2-methoxyphenyl) [2,3-dichloro-4-(*trans*-2-(2-carboxypiperidin-1-



yl)carbonyl)cycloprop-1-yl)phenyl]sulfide and (2-methoxyphenyl)[2,3-dichloro-4-(*trans*-(2-((3-(1-pyrrolidin-2-onyl)-prop-1-ylamino)carbonyl)cycloprop-1-yl)phenyl]sulfide.

5           8. A composition comprising:

a compound of claim 1

in a pharmaceutically acceptable carrier.

9. A method of inhibiting inflammation or suppressing immune response in  
10 a mammal comprising administering to said mammal a therapeutic amount  
of a compound of claim 1.

## INTERNATIONAL SEARCH REPORT

In **onal Application No**

PCT/US 01/20156

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C07D207/26 C07C323/62 C07D211/60 C07D295/08 C07D211/62  
 C07D295/18 C07D205/04 C07D295/12 C07D401/12 A61K31/33  
 A61K31/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BEILSTEIN Data, EPO-Internal, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 27947 A (RHONE-POULENC RORER LTD) 8 December 1994 (1994-12-08) examples; claims ---	1,8,9
A	WO 99 47497 A (MERCK FROSST CANADA & CO) 23 September 1999 (1999-09-23) claims 1-23 ---	1,8,9
P,X	J.T. LINK ET AL: BIOORG. MED. CHEM. LETT., vol. 11, no. 8, 23 April 2001 (2001-04-23), pages 973-976, XP000926637 the whole document ---	1-9
P,A	WO 00 39081 A (ABOTT LABORATORIES) 6 July 2000 (2000-07-06) examples; claims -----	1,8,9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

13 November 2001

Date of mailing of the international search report

20/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/20156

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9427947	A	08-12-1994	AU	6803594 A	20-12-1994
			WO	9427947 A1	08-12-1994
WO 9947497	A	23-09-1999	AU	2708699 A	11-10-1999
			WO	9947497 A2	23-09-1999
			EP	1071648 A2	31-01-2001
			US	6242493 B1	05-06-2001
WO 0039081	A	06-07-2000	US	6110922 A	29-08-2000
			AU	2220300 A	31-07-2000
			EP	1140814 A2	10-10-2001
			NO	20013241 A	28-08-2001
			WO	0039081 A2	06-07-2000